We		O
also		O
demonstrated		O
that		O
the		O
substituents		O
on		O
the		O
quinazoline		O
ring		O
possess		O
major		O
consequences		O
for		O
metabolic		O
polymorphism		O
.		O
In		O
order		O
to		O
obtain		O
agents		O
with		O
therapeutic		O
indices		O
superior		O
to		O
those		O
of		O
AZT		O
,		O
FLT		O
,		O
or		O
D4T		O
,		O
several		O
analogues		O
of		O
anti		O
-		O
HIV		O
-		O
1		O
nucleosides		O
were		O
synthesized		O
.		O
The		O
alkylating		O
agent		O
[		O
(		O
11		O
)		O
C		O
]		O
10		O
or		O
[		O
(		O
11		O
)		O
C		O
]		O
11		O
was		O
prepared		O
by		O
reacting		O
CH		O
(		O
3		O
)		O
MgBr		O
with		O
[		O
(		O
11		O
)		O
C		O
]		O
CO		O
(		O
2		O
)		O
,		O
followed		O
by		O
reduction		O
with		O
LiAlH		O
(		O
4		O
)		O
and		O
iodination		O
with		O
HI		O
.		O
No		O
ATP		O
-		O
site		O
-		O
directed		O
inactivations		O
resulted		O
when		O
the		O
M		O
,		O
L		O
,		O
or		O
K		O
isozymes		O
of		O
PK		O
were		O
exposed		O
for		O
8		O
h		O
,		O
22		O
degrees		O
C		O
,		O
to		O
5		O
mM		O
levels		O
of		O
18		O
ATP		O
derivatives		O
or		O
6		O
analogous		O
ADP		O
derivatives		O
or		O
when		O
yeast		O
HK		O
or		O
rat		O
KH		O
I		O
,		O
II		O
,		O
or		O
III		O
was		O
exposed		O
for		O
6		O
h		O
,		O
22		O
degrees		O
C		O
,		O
to		O
5		O
mM		O
levels		O
of		O
28		O
ATP		O
derivatives		O
.		O
For		O
example		O
,		O
the		O
most		O
potent		O
derivative		O
,		O
3		B-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
naphtho		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
acetic		I-IUPAC
acid		I-IUPAC
with		O
an		O
IC50		O
of		O
0.020		O
microM		O
,		O
is		O
as		O
potent		O
as		O
sorbinil		O
(		O
IC50		O
=		O
0.017		O
microM		O
)		O
in		O
the		O
crude		O
rat		O
lens		O
aldose		O
reductase		O
assay		O
.		O
The		O
observed		O
order		O
of		O
activity		O
was		O
3d		O
greater		O
than		O
3c		O
greater		O
than		O
3b		O
greater		O
than		O
3a		O
.		O
Treatment		O
of		O
thymidine		O
with		O
trimethylsilyl		O
chloride		O
and		O
then		O
with		O
phosphoryl		O
chloride		O
and		O
1,2,4		B-IUPAC
-		I-IUPAC
triazole		I-IUPAC
gave		O
upon		O
workup		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
5		O
)		O
.		O
The		O
radioiodinations		O
of		O
all		O
compounds		O
with		O
[		O
(		O
131		O
)		O
I		O
]		O
I		O
(		O
-		O
)		O
were		O
performed		O
with		O
radiochemical		O
yields		O
of		O
&		O
gt		O
;		O
70%		O
for		O
the		O
destannylation		O
of		O
the		O
corresponding		O
tri		O
-		O
n		O
-		O
butylstannylated		O
precursors		O
.		O
1,3		B-IUPAC
-		I-IUPAC
Dimethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylpiperazinopropylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
,		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
pyrimido		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
f		I-IUPAC
]		I-IUPAC
purine		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
(		O
20		O
)		O
behaved		O
like		O
an		O
agonist		O
of		O
presynaptic		O
and		O
as		O
a		O
partial		O
agonist		O
of		O
postsynaptic		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptors		O
and		O
resembled		O
ipsapirone		O
in		O
terms		O
of		O
functional		O
intrinsic		O
activity		O
.		O
With		O
only		O
one		O
exception		O
,		O
methyl		B-IUPAC
6		I-IUPAC
-		I-IUPAC
benzoylimidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamate		I-IUPAC
,		O
both		O
classes		O
of		O
compounds		O
exhibited		O
similar		O
activity		O
vs.		O
Nematospiroides		O
dubius		O
in		O
mice		O
.		O
In		O
the		O
present		O
work		O
,		O
we		O
describe		O
how		O
the		O
bicyclo		B-IUPAC
[		I-IUPAC
3.1.0		I-IUPAC
]		I-IUPAC
hexane		I-IUPAC
template		O
fixes		O
the		O
ring		O
pucker		O
of		O
2'		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
methanocarba		I-IUPAC
-		I-IUPAC
nucleosides		I-IUPAC
1-5		O
and		O
12		O
to		O
values		O
corresponding		O
to		O
either		O
one		O
of		O
these		O
two		O
extreme		O
conformations		O
that		O
are		O
typical		O
of		O
nucleosides		O
.		O
The		O
1		B-PARTIUPAC
-		I-PARTIUPAC
butyl		I-PARTIUPAC
-		I-PARTIUPAC
(		O
37		O
and		O
39		O
)		O
and		O
1		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
methoxyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
(		O
38		O
and		O
40		O
)		O
5		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
benzyluracils		I-IUPAC
were		O
synthesized		O
by		O
1		O
-		O
alkylation		O
of		O
the		O
3		B-IUPAC
-		I-IUPAC
phenacyl		I-IUPAC
derivatives		B-MODIFIER
35		O
and		O
36		O
with		O
alkyl		O
halides		O
followed		O
by		O
deprotection		O
of		O
the		O
3		B-IUPAC
-		I-IUPAC
phenacyl		I-IUPAC
group		B-MODIFIER
.		O
None		O
of		O
the		O
compounds		O
was		O
as		O
potent		O
as		O
TMQ		O
or		O
PTX		O
,		O
and		O
while		O
some		O
of		O
them		O
showed		O
some		O
selectivity		O
in		O
their		O
binding		O
to		O
Pneumocystis		O
carinii		O
and		O
Toxoplasma		O
gondii		O
versus		O
rat		O
liver		O
DHFR		O
,		O
this		O
effect		O
was		O
not		O
deemed		O
large		O
enough		O
to		O
warrant		O
further		O
preclinical		O
evaluation		O
.		O
The		O
activity		O
profiles		O
of		O
5k		O
,		O
l		O
were		O
generally		O
similar		O
to		O
that		O
of		O
5j		O
except		O
that		O
there		O
were		O
no		O
cells		O
against		O
which		O
the		O
IC50		O
was		O
&		O
lt		O
;		O
0.01		O
microM		O
.		O
For		O
the		O
ketones		O
,		O
the		O
order		O
is		O
24		O
-		O
one		O
&		O
gt		O
;		O
or		O
=		O
23		O
-		O
one		O
&		O
gt		O
;		O
20		O
-		O
one		O
&		O
gt		O
;		O
22		O
-		O
one		O
.		O
Size		O
and		O
planarity		O
of		O
the		O
aromatic		O
side		O
chain		O
were		O
crucially		O
important		O
for		O
the		O
biological		O
activity		O
,		O
whereas		O
electron		O
-		O
donating		O
and		O
electron		O
-		O
withdrawing		O
properties		O
of		O
the		O
para		O
-		O
substituent		O
were		O
less		O
important		O
.		O
Compound		O
1a		O
,		O
the		O
most		O
potent		O
isomer		O
of		O
the		O
series		O
,		O
was		O
also		O
tested		O
in		O
vivo		O
on		O
pithed		O
rat		O
and		O
its		O
muscarinic		O
activity		O
at		O
the		O
M1		O
receptor		O
subtype		O
was		O
compared		O
with		O
that		O
of		O
muscarine		O
.		O
Affinity		O
at		O
the		O
H2		O
receptors		O
,		O
evaluated		O
from		O
antagonism		O
of		O
histamine		O
-		O
stimulated		O
chronotropic		O
response		O
on		O
guinea		O
pig		O
atria		O
,		O
increased		O
following		O
fluorine		O
substitution		O
(		O
3a		O
,		O
KB		O
=		O
177		O
;		O
3b		O
,		O
KB		O
=		O
61		O
;		O
3c		O
,		O
KB		O
=		O
21		O
;		O
3d		O
,		O
KB		O
=		O
7.6		O
)		O
.		O
Preferred		O
substituents		O
on		O
the		O
triazolinone		O
ring		O
were		O
n		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
at		O
C5		O
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
at		O
N2		O
.		O
A		O
potent		O
and		O
orally		O
active		O
NK1		O
antagonist		O
,		O
trans		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
,		I-IUPAC
5		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
benzyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
N		I-IUPAC
,		I-IUPAC
7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1,7		I-IUPAC
-		I-IUPAC
naphthyridine		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
1t		O
)		O
,		O
was		O
shown		O
to		O
exist		O
as		O
a		O
mixture		O
of		O
separable		O
and		O
stable		O
(		O
R		O
)		O
-		O
and		O
(		O
S		O
)		O
-		O
atropisomers		O
(		O
1t		O
-		O
A		O
and		O
1t		O
-		O
B		O
)		O
originating		O
from		O
the		O
restricted		O
rotation		O
around		O
the		O
-		O
C		O
(		O
6		O
)		O
-		O
C		O
(		O
=		O
O		O
)		O
-		O
bond		O
;		O
the		O
antagonistic		O
activities		O
of		O
1t		O
-		O
A		O
were		O
ca.		O
6-13		O
-		O
fold		O
higher		O
than		O
those		O
of		O
1t		O
-		O
B		O
.		O
The		O
activity		O
of		O
13		O
against		O
P		O
.		O
Chemical		O
functionality		O
incorporated		O
in		O
the		O
thioether		O
moiety		O
included		O
cyanoalkyl		O
,		O
nitroaromatic		O
,		O
amino		B-IUPAC
,		O
thiol		B-IUPAC
,		O
cycloalkyl		O
,		O
n		O
-		O
alkyl		O
,		O
and		O
olefinic		O
groups		O
.		O
The		O
five		O
acids		O
are		O
4		B-IUPAC
-		I-IUPAC
fluorobenzoic		I-IUPAC
acid		I-IUPAC
(		O
FB		O
,		O
2b		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylbenzoic		I-IUPAC
acid		I-IUPAC
(		O
MeFB		O
,		O
2c		O
)		O
,		O
trans		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorocyclohexanecarboxylic		I-IUPAC
acid		I-IUPAC
(		O
FC		O
,		O
2d		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoromethyl		I-IUPAC
)		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
FMeB		O
,		O
2e		O
)		O
,		O
and		O
3		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoromethyl		I-IUPAC
)		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
NFMeB		O
,		O
2f		O
)		O
(		O
see		O
Scheme		O
1		O
)		O
.		O
Even		O
though		O
8a		O
and		O
8b		O
were		O
found		O
to		O
be		O
curative		O
in		O
a		O
high		O
percentage		O
of		O
mice		O
bearing		O
ip		O
implanted		O
partially		O
ara		O
-		O
C		O
resistant		O
L1210		O
subline		O
[		O
L1210		O
/		O
ara		O
-		O
C		O
(		O
I		O
)		O
]		O
,		O
they		O
were		O
completely		O
ineffective		O
against		O
deoxycytidine		O
kinase		O
deficient		O
ara		O
-		O
C		O
resistant		O
L1210		O
subline		O
[		O
L1210		O
/		O
ara		O
-		O
C		O
(		O
II		O
)		O
]		O
.		O
Thus		O
,		O
the		O
derivatives		O
39		O
,		O
46		O
,		O
and		O
61		O
bound		O
with		O
higher		O
affinity		O
and		O
selectivity		O
to		O
5		O
-		O
HT1A		O
receptors		O
(		O
versus		O
dopaminergic		O
D2		O
and		O
adrenergic		O
alpha1		O
receptors		O
)		O
and		O
displayed		O
more		O
potent		O
5		O
-		O
HT1A		O
agonist		O
activity		O
in		O
vitro		O
and		O
in		O
vivo		O
than		O
their		O
C		O
-		O
4		O
desfluoro		O
analogues		O
.		O
Three		O
were		O
bromoacetamides		O
differing		O
at		O
the		O
alkyl		O
substituent		O
(		O
methyl		O
,		O
ethyl		O
,		O
or		O
propyl		O
)		O
,		O
and		O
the		O
last		O
was		O
an		O
[		B-IUPAC
(		I-IUPAC
iodoacetamido		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
estradiol		I-IUPAC
prepared		O
under		O
both		O
nonradioactive		O
and		O
3H		O
-		O
labeled		O
forms		O
.		O
Deprotection		O
of		O
18		O
with		O
tetra		B-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butylammonium		I-IUPAC
fluoride		I-IUPAC
and		O
ring		O
annulation		O
with		O
hydrazine		O
afforded		O
20		O
.		O
It		O
is		O
interesting		O
to		O
note		O
that		O
the		O
alpha		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluorocytosine		I-IUPAC
analogue		B-MODIFIER
exhibited		O
an		O
excellent		O
anti		O
-		O
HIV		O
activity		O
(		O
EC50		O
=		O
0.063		O
microM		O
)		O
without		O
cytotoxicity		O
up		O
to		O
100		O
microM		O
in		O
PBM		O
cell		O
.		O
Conversion		O
to		O
the		O
4		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
derivatives		B-MODIFIER
and		O
condensation		O
with		O
3		B-IUPAC
-		I-IUPAC
chloroaniline		I-IUPAC
gave		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chloroanilino		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
.		O
The		O
[		O
125I		O
]		O
-		O
radiolabeled		O
congeners		O
of		O
10		O
and		O
14		O
were		O
prepared		O
as		O
potential		O
metabolic		O
markers		O
.		O
This		O
compound		O
is		O
1'		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
spiro		I-IUPAC
[		I-IUPAC
isobenzofuran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
piperidine		I-IUPAC
]		I-IUPAC
,		O
14f		O
(		O
code		O
no		O
.		O
Because		O
of		O
the		O
high		O
potency		O
and		O
selectivity		O
of		O
19		O
,		O
this		O
compound		O
has		O
also		O
been		O
prepared		O
in		O
the		O
[		O
125I		O
]		O
-		O
iodinated		O
form		O
by		O
a		O
nucleophilic		O
halogen		O
exchange		O
reaction		O
using		O
the		O
corresponding		O
bromo		O
derivative		O
22		O
as		O
a		O
precursor		O
.		O
The		O
same		O
phenomenon		O
had		O
been		O
observed		O
for		O
the		O
DENSPM		O
/		O
(		O
2R		O
,		O
10R		O
)		O
-		O
(		O
HO		O
)		O
(		O
2		O
)		O
DENSPM		O
pair		O
.		O
The		O
N		O
(		O
1		O
)		O
-		O
substituents		O
included		O
benzyl		B-IUPAC
,		O
naphthalen		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
,		O
anthracen		B-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
,		O
and		O
pyren		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
.		O
The		O
7		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
and		O
the		O
7		B-IUPAC
-		I-IUPAC
trifluoromethyl		I-IUPAC
derivatives		B-MODIFIER
10b		O
,		O
f		O
have		O
demonstrated		O
high		O
potency		O
(		O
0.4		O
and		O
0.3		O
microM		O
)		O
and		O
excellent		O
selectivity		O
(		O
HCR		O
=		O
250		O
and		O
340		O
)		O
.		O
LiAlH4		O
reduction		O
of		O
3		O
gave		O
9,11		B-IUPAC
-		I-IUPAC
seco		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
hydroxyestradiol		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
ether		I-IUPAC
(		O
11		O
)		O
which		O
on		O
demethylation		O
gave		O
9,11		B-IUPAC
-		I-IUPAC
seco		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
hydroxyestradiol		I-IUPAC
(		O
12		O
)		O
.		O
Two		O
examples		O
,		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
dicyanoimidazole		I-IUPAC
(		O
16		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitroimidazole		I-IUPAC
(		O
3		O
)		O
,		O
were		O
at		O
least		O
an		O
order		O
of		O
magnitude		O
more		O
active		O
than		O
the		O
standards		O
and		O
therefore		O
rank		O
among		O
the		O
most		O
potent		O
known		O
inhibitors		O
of		O
the		O
enzyme		O
.		O
Desulfurization		O
of		O
these		O
thioureas		O
by		O
Raney		O
nickel		O
furnished		O
the		O
desired		O
formamidines		O
(		O
3b		O
-		O
d		O
)		O
.		O
The		O
results		O
obtained		O
through		O
site		O
-		O
directed		O
mutagenic		O
analysis		O
support		O
our		O
predicted		O
binding		O
models		O
for		O
these		O
ligands		O
and		O
provide		O
new		O
insights		O
into		O
PKC		O
-		O
ligand		O
binding		O
.		O
Vasotocin		O
(		O
AVT		O
)		O
analogues		O
with		O
tyrosine		O
or		O
phenylalanine		O
in		O
position		O
9		O
,		O
i.e.		O
,		O
[		O
9		B-IUPAC
-		I-IUPAC
tyrosine		I-IUPAC
]		O
AVT		O
,		O
[		O
2		B-IUPAC
-		I-IUPAC
phenylalanine		I-IUPAC
,		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
tyrosine		I-IUPAC
]		O
AVT		O
,		O
and		O
1		B-IUPAC
-		I-IUPAC
desamino		I-IUPAC
[		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
aminophenylalanine		I-IUPAC
)		I-IUPAC
]		I-IUPAC
AVT		O
,		O
were		O
synthesized		O
by		O
the		O
solid		O
-		O
phase		O
method		O
.		O
For		O
the		O
preparation		O
of		O
5e		O
a		O
new		O
ring		O
-		O
closure		O
method		O
was		O
applied		O
.		O
HPLC		O
analyses		O
and		O
circular		O
dichroism		O
spectroscopy		O
indicated		O
the		O
absolute		O
stereochemistry		O
of		O
8		O
and		O
9		O
to		O
be		O
S		O
and		O
R		O
,		O
respectively		O
.		O
After		O
selective		O
tritylation		O
of		O
the		O
tetrazole		O
rings		O
in		O
3		O
and		O
4		O
,		O
treatment		O
of		O
N		B-MODIFIER
-		I-MODIFIER
tritylated		I-MODIFIER
benzimidazole		B-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acids		I-IUPAC
(		O
6		O
,		O
7		O
)		O
with		O
a		O
variety		O
of		O
alkyl		O
halides		O
,		O
followed		O
by		O
deprotection		O
with		O
hydrochloric		O
acid		O
,		O
afforded		O
esters		O
of		O
3		O
and		O
4		O
.		O
Biol.		O
Chem.		O
1983		O
,		O
258		O
,		O
15046-15053		O
.		O
Compound		O
(		O
-		O
)		O
-		O
2		O
is		O
the		O
most		O
selective		O
of		O
this		O
group		O
(		O
16		O
-		O
fold		O
)		O
for		O
the		O
sigma		O
1		O
subtype		O
versus		O
sigma		O
2		O
.		O
All		O
the		O
new		O
synthesized		O
pyrimidines		O
were		O
evaluated		O
in		O
spontaneously		O
beating		O
and		O
electrically		O
driven		O
atria		O
from		O
reserpine		O
-		O
treated		O
guinea		O
pigs		O
.		O
The		O
NAD		O
analogue		O
23b		O
was		O
also		O
prepared		O
by		O
the		O
treatment		O
of		O
17		O
with		O
an		O
activated		O
form		O
of		O
AMP		O
in		O
the		O
presence		O
of		O
AgNO3		O
.		O
Molecular		O
modeling		O
studies		O
show		O
that		O
the		O
4		O
-		O
carbonyl		O
groups		O
of		O
the		O
kynurenic		O
acids		O
,		O
the		O
tetrahydroquinolines		O
,		O
and		O
related		O
antagonists		O
based		O
on		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
glycine		I-IUPAC
,		O
can		O
interact		O
with		O
a		O
single		O
putative		O
H		O
-		O
bond		O
donor		O
on		O
the		O
receptor		O
.		O
The		O
compounds		O
were		O
designed		O
as		O
potential		O
ACE		O
inhibitors		O
of		O
novel		O
structure		O
,		O
assuming		O
that		O
a		O
monoamidic		O
residue		O
of		O
an		O
1,2		B-IUPAC
-		I-IUPAC
cyclomethylenedicarboxylic		I-IUPAC
acid		I-IUPAC
could		O
be		O
an		O
alternative		O
structure		O
to		O
the		O
acylproline		O
moiety		O
,		O
the		O
carboxyl		O
-		O
terminal		O
portion		O
common		O
to		O
various		O
ACE		O
inhibitors		O
.		O
Conformational		O
analyses		O
show		O
that		O
these		O
isomers		O
exist		O
in		O
a		O
flattened		O
boat		O
conformation		O
with		O
pseudoequatorial		O
substituents		O
.		O
The		O
thermal		O
Fischer		O
indolization		O
of		O
hydrazones		O
resulting		O
from		O
4		B-IUPAC
-		I-IUPAC
hydrazino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
one		I-IUPAC
and		O
various		O
beta		B-PARTIUPAC
-		I-PARTIUPAC
and		O
alpha		B-IUPAC
-		I-IUPAC
tetralones		I-IUPAC
led		O
to		O
4		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
,		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
4,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
e		I-IUPAC
]		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
and		O
4		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
,		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
4,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
g		I-IUPAC
]		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
,		O
respectively		O
.		O
The		O
observed		O
lower		O
cytotoxicity		O
in		O
the		O
PAT		O
-		O
deficient		O
CHO		O
-		O
MG		O
cell		O
line		O
supported		O
the		O
premise		O
that		O
the		O
conjugates		O
use		O
PAT		O
for		O
cellular		O
entry		O
.		O
Many		O
compounds		O
within		O
this		O
piperazine		O
series		O
of		O
[		B-IUPAC
1,2,4		I-IUPAC
]		I-IUPAC
triazolo		I-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
triazine		I-IUPAC
have		O
now		O
been		O
shown		O
to		O
have		O
good		O
oral		O
bioavailability		O
in		O
the		O
rat		O
,		O
with		O
some		O
as		O
high		O
as		O
89%		O
(		O
compound		O
35		O
)		O
.		O
TFPe		O
-		O
dUrd		O
demonstrated		O
a		O
potent		O
and		O
unusually		O
selective		O
activity		O
against		O
HSV		O
-		O
1		O
,		O
with		O
a		O
2		O
-		O
log		O
reduction		O
in		O
virus		O
yield		O
at		O
0.03		O
micrograms		O
/		O
mL		O
(		O
0.09		O
microM		O
)		O
;		O
L		O
-		O
1210		O
cell		O
growth		O
was		O
inhibited		O
by		O
50%		O
only		O
at		O
290		O
micrograms		O
/		O
mL		O
.		O
Compound		O
7n		O
is		O
a		O
13		O
-		O
fold		O
more		O
potent		O
inhibitor		O
than		O
7b		O
,		O
and		O
these		O
kinetic		O
studies		O
indicate		O
that		O
the		O
increase		O
in		O
inhibitory		O
activity		O
is		O
due		O
to		O
an		O
increase		O
in		O
initial		O
affinity		O
toward		O
the		O
enzyme		O
and		O
not		O
an		O
increase		O
in		O
chemical		O
reactivity		O
.		O
4		B-PARTIUPAC
-		I-PARTIUPAC
Nitrobenzene		I-PARTIUPAC
-		I-PARTIUPAC
and		O
4		B-IUPAC
-		I-IUPAC
chlorobenzenesulfonamides		I-IUPAC
containing		O
both		O
N		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
substituents		B-MODIFIER
were		O
model		O
irreversible		O
inhibitors		O
of		O
carbonic		O
anhydrase		O
and		O
exhibited		O
a		O
trend		O
toward		O
topical		O
activity		O
in		O
reducing		O
IOP		O
in		O
normotensive		O
rabbit		O
eyes		O
.		O
Inhibition		O
of		O
[		O
3H		O
]		O
AMPA		O
binding		O
by		O
ATPA		O
was		O
1		O
order		O
of		O
magnitude		O
weaker		O
than		O
that		O
of		O
AMPA		O
,		O
in		O
agreement		O
with		O
the		O
relative		O
potency		O
of		O
these		O
compounds		O
in		O
vivo		O
.		O
Thrombin		O
is		O
a		O
serine		O
protease		O
responsible		O
for		O
blood		O
coagulation		O
.		O
A		O
novel		O
reagent		O
,		O
maleimidoethyl		B-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butylstannyl		I-IUPAC
)		I-IUPAC
hippurate		I-IUPAC
(		O
MIH		O
)		O
,		O
was		O
synthesized		O
by		O
reacting		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxyethyl		I-IUPAC
)		I-IUPAC
maleimide		I-IUPAC
with		O
N		B-IUPAC
-		I-IUPAC
Boc		I-IUPAC
-		I-IUPAC
glycine		I-IUPAC
before		O
coupling		O
with		O
N		B-IUPAC
-		I-IUPAC
succinimidyl		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butylstannyl		I-IUPAC
)		I-IUPAC
benzoate		I-IUPAC
(		O
ATE		O
)		O
.		O
However		O
,		O
oral		O
activity		O
in		O
the		O
PAF		O
-		O
induced		O
bronchoconstriction		O
model		O
was		O
highly		O
sensitive		O
to		O
the		O
nature		O
and		O
substitution		O
of		O
the		O
bicyclic		O
ring		O
system		O
.		O
A		O
3		O
-		O
substituent		O
on		O
the		O
piperidine		O
ring		O
was		O
necessary		O
for		O
antiplatelet		O
activity		O
;		O
the		O
substituent		O
should		O
be		O
preferably		O
an		O
amide		O
with		O
its		O
C		O
attached		O
directly		O
to		O
the		O
ring		O
.		O
Synthesis		O
and		O
biological		O
activities		O
of		O
12		O
analogs		O
of		O
N6		B-IUPAC
-		I-IUPAC
benzyladenosine		I-IUPAC
are		O
described		O
.		O
In		O
general		O
,		O
the		O
derivatives		O
were		O
found		O
to		O
be		O
considerably		O
more		O
potent		O
at		O
24		O
h		O
than		O
at		O
2		O
h		O
after		O
the		O
administration		O
.		O
The		O
order		O
of		O
efficiency		O
was		O
[		B-IUPAC
(		I-IUPAC
bromoacetamido		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
estradiol		I-IUPAC
&		O
lt		O
;		O
[		B-IUPAC
(		I-IUPAC
bromoacetamido		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
estradiol		I-IUPAC
&		O
lt		O
;		O
&		O
lt		O
;		O
[		B-IUPAC
(		I-IUPAC
bromoacetamido		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
estradiol		I-IUPAC
&		O
lt		O
;		O
[		B-IUPAC
(		I-IUPAC
iodoacetamido		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
estradiol		I-IUPAC
.		O
In		O
this		O
case		O
,		O
both		O
cis		O
and		O
trans		O
isomers		O
showed		O
equally		O
weak		O
in		O
vitro		O
5		O
-		O
HT1A		O
receptor		O
agonist		O
activity		O
devoid		O
of		O
dopaminergic		O
effects		O
.		O
In		O
general		O
,		O
compounds		O
having		O
two		O
different		O
R1		O
and		O
R2		O
substituents		O
in		O
the		O
4,5		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dioxolane		I-IUPAC
moiety		B-MODIFIER
were		O
more		O
water		O
-		O
soluble		O
than		O
those		O
having		O
the		O
same		O
substituents		O
.		O
The		O
diphenylmethyl		O
moiety		O
functioned		O
as		O
an		O
effective		O
isostere		O
for		O
4,5		O
-		O
diphenylated		O
heterocycles		O
since		O
13aad		O
showed		O
similar		O
platelet		O
inhibitory		O
activity		O
to		O
3		O
.		O
Most		O
members		O
of		O
this		O
series		O
showed		O
the		O
excellent		O
antitumor		O
activity		O
against		O
murine		O
L1210		O
leukemia		O
cells		O
transplanted		O
in		O
mice		O
and		O
were		O
superior		O
to		O
cisplatin		O
and		O
carboplatin		O
.		O
5		O
-		O
(		O
4		O
-		O
Piperidyl		O
)		O
isoxazol		O
-		O
3		O
-		O
ol		O
(		O
4		O
-		O
PIOL		O
,		O
10		O
)		O
,		O
a		O
structural		O
analog		O
of		O
4		B-IUPAC
-		I-IUPAC
aminobutanoic		I-IUPAC
acid		I-IUPAC
(		O
GABA		O
,		O
1		O
)		O
and		O
the		O
GABAA		O
agonist		O
4,5,6,7		B-IUPAC
-		I-IUPAC
tetrahydroisoxazolo		I-IUPAC
[		I-IUPAC
5,4		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
THIP		O
,		O
5		O
)		O
,		O
is		O
a		O
low		O
-		O
efficacy		O
partial		O
GABAA		O
agonist		O
.		O
The		O
resulting		O
diastereoisomers		O
were		O
separated		O
by		O
column		O
chromatography		O
and		O
their		O
structures		O
established		O
by		O
CD		O
and		O
NMR		O
spectroscopy		O
.		O
Quantitative		O
autoradiographic		O
techniques		O
were		O
utilized		O
in		O
regional		O
analyses		O
of		O
antagonist		O
binding		O
.		O
A		O
series		O
of		O
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2		B-IUPAC
-		I-IUPAC
formylpyridine		I-IUPAC
thiosemicarbazones		I-IUPAC
has		O
been		O
synthesized		O
which		O
contain		O
a		O
tertiary		O
N		O
at		O
the		O
4		O
position		O
.		O
Three		O
electrophilic		O
amide		O
analogues		O
of		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
diaminopropionic		I-IUPAC
acid		I-IUPAC
(		O
1		O
,		O
DAP		O
)		O
have		O
been		O
prepared		O
as		O
potential		O
inhibitors		O
of		O
L		O
-		O
asparagine		O
synthetase		O
(		O
ASase		O
,		O
from		O
Novikoff		O
hepatoma		O
,		O
EC		O
6.3.5.4		O
)		O
.		O
Thermal		O
decomposition		O
of		O
9b		O
and		O
9c		O
at		O
110		O
degrees		O
C		O
in		O
dioxane		O
yielded		O
corresponding		O
5		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azirinyl		I-IUPAC
)		I-IUPAC
]		I-IUPAC
uracil		I-IUPAC
analogues		B-MODIFIER
(		O
10b		O
,		O
c		O
)		O
.		O
The		O
somatostatin		O
receptor		O
binding		O
affinities		O
of		O
synthetic		O
DTPA		O
-		O
D		O
-		O
Phe1		O
-		O
octreotide		O
and		O
CPTA		O
-		O
D		O
-		O
Phe1		O
-		O
octreotide		O
to		O
AtT		O
-		O
20		O
mouse		O
pituitary		O
carcinoma		O
cell		O
membranes		O
were		O
examined		O
by		O
labeling		O
with		O
111In		O
and		O
64Cu		O
,		O
respectively		O
,		O
and		O
performing		O
Scatchard		O
analyses		O
.		O
Some		O
of		O
the		O
7		O
-		O
oxa		O
-		O
7,8		O
-		O
dihydro		O
-		O
RAs		O
bind		O
to		O
CRABP		O
and		O
RARalpha		O
.		O
The		O
in		O
vitro		O
inotropic		O
activity		O
of		O
these		O
compounds		O
,		O
as		O
well		O
as		O
the		O
known		O
cardiotonics		O
amrinone		O
and		O
7		B-IUPAC
-		I-IUPAC
hydroxycyclindole		I-IUPAC
(		O
7		O
)		O
,		O
was		O
investigated		O
.		O
The		O
most		O
interesting		O
compounds		O
included		O
[		B-IUPAC
R		I-IUPAC
-		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propenamide		I-IUPAC
(		O
4b		O
)		O
,		O
[		B-IUPAC
R		I-IUPAC
-		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiophene		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propenamide		I-IUPAC
(		O
4k		O
)		O
,		O
and		O
[		B-IUPAC
R		I-IUPAC
-		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
indoly		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propenamide		I-IUPAC
(		O
4l		O
)		O
which		O
inhibited		O
PAF		O
-		O
induced		O
broncho		O
-		O
constriction		O
in		O
guinea		O
pigs		O
with		O
IC50s		O
of		O
3.0-5.4		O
mg		O
/		O
kg		O
,		O
when		O
the		O
animals		O
were		O
challenged		O
2		O
h		O
after		O
drug		O
treatment		O
.		O
As		O
the		O
most		O
effective		O
route		O
,		O
Newman		O
-		O
Kwart		O
rearrangement		O
of		O
benzazocines		O
was		O
selected		O
and		O
closely		O
investigated		O
.		O
The		O
results		O
revealed		O
that		O
the		O
H4a		O
,		O
H5		O
-		O
cis		O
,		O
H4a		O
,		O
H9b		O
-		O
cis		O
series		O
and		O
the		O
ortho		O
-		O
substituted		O
5		O
-		O
phenyl		O
H4a		O
,		O
H5		O
-		O
trans		O
,		O
H4a		O
,		O
H9b		O
-		O
cis		O
compounds		O
lack		O
activity		O
.		O
In		O
functional		O
selectivity		O
experiments		O
,		O
10		O
,		O
13		O
,		O
and		O
14		O
did		O
not		O
stimulate		O
H		O
(		O
2		O
)		O
,		O
H		O
(		O
3		O
)		O
,		O
and		O
several		O
other		O
neurotransmitter		O
receptors		O
.		O
The		O
object		O
of		O
the		O
study		O
was		O
to		O
determine		O
the		O
structural		O
factors		O
governing		O
sigma		O
1		O
/		O
sigma		O
2		O
affinity		O
and		O
selectivity		O
within		O
this		O
class		O
of		O
compounds		O
.		O
Their		O
inhibitory		O
effect		O
on		O
AII		O
-		O
induced		O
pressor		O
response		O
in		O
rats		O
and		O
oral		O
BA		O
were		O
investigated		O
.		O
None		O
of		O
the		O
new		O
compounds		O
were		O
estrogenic		O
in		O
the		O
3		O
-		O
day		O
immature		O
mouse		O
uterotrophic		O
assay		O
at		O
doses		O
up		O
to		O
750		O
micrograms		O
.		O
Given		O
significant		O
binding		O
to		O
one		O
or		O
more		O
EAA		O
receptors		O
,		O
5		O
would		O
offer		O
unique		O
modeling		O
and		O
perhaps		O
biological		O
opportunities		O
.		O
In		O
comparison		O
to		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
diethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
5		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
androstane		I-IUPAC
-		I-IUPAC
17		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
4		O
-		O
MA		O
;		O
IC50		O
=		O
4.15		O
nM		O
)		O
,		O
17		B-IUPAC
beta		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
alkylformamido		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
azasteroids		I-IUPAC
were		O
potent		O
inhibitors		O
of		O
human		O
type		O
I		O
5		O
alpha		O
-		O
reductase		O
,		O
IC50		O
values		O
of		O
compounds		O
29		O
,		O
30		O
,		O
36		O
,		O
and		O
37		O
being		O
measured		O
as		O
3.05		O
,		O
0.91		O
,		O
2.19		O
,		O
and		O
2.35		O
nM		O
,		O
respectively		O
.		O
They		O
also		O
demonstrated		O
high		O
affinity		O
and		O
selectivity		O
for		O
the		O
5		O
-		O
HT1A		O
receptor		O
site		O
(		O
Ki		O
=		O
10		O
nM		O
)		O
and		O
exhibited		O
partial		O
agonist		O
/		O
antagonist		O
activity		O
in		O
the		O
serotonin		O
syndrome		O
test		O
.		O
Ring		O
closure		O
of		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
ethanone		I-IUPAC
dihydrochloride		I-IUPAC
(		O
3		O
)		O
with		O
triethyl		B-IUPAC
orthoacetate		I-IUPAC
or		O
triethyl		B-IUPAC
orthopropionate		I-IUPAC
gave		O
the		O
C		B-MODIFIER
-		I-MODIFIER
5		I-MODIFIER
methyl		B-IUPAC
and		O
ethyl		B-IUPAC
ketoaglycons		I-IUPAC
,		O
6,7		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,3		I-IUPAC
]		I-IUPAC
diazepin		I-IUPAC
-		I-IUPAC
8		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
4b		O
)		O
and		O
5		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
dihydroimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,3		I-IUPAC
]		I-IUPAC
diazepin		I-IUPAC
-		I-IUPAC
8		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
4c		O
)		O
,		O
respectively		O
.		O
Phenyl		O
-		O
substituted		O
etoxadrol		O
analogues		O
were		O
compared		O
to		O
similarly		O
substituted		O
PCP		O
analogues		O
and		O
distinct		O
differences		O
were		O
found		O
in		O
their		O
structure		O
-		O
activity		O
relationships		O
suggesting		O
that		O
the		O
aromatic		O
rings		O
in		O
these		O
two		O
drug		O
classes		O
interact		O
differently		O
with		O
the		O
PCP		O
binding		O
sites		O
.		O
Types		O
6		O
and		O
7		O
compounds		O
were		O
more		O
potent		O
than		O
the		O
corresponding		O
type		O
5		O
molecules		O
.		O
carinii		O
trophozoites		O
in		O
culture		O
at		O
a		O
concentration		O
of		O
10		O
microgram		O
/		O
mL		O
and		O
was		O
found		O
to		O
completely		O
suppress		O
growth		O
over		O
7		O
days		O
.		O
The		O
Trp		O
(		O
DNPS		O
)		O
-		O
containing		O
analogue		O
was		O
neurotoxic		O
.		O
To		O
develop		O
potent		O
H3		O
and		O
H4		O
receptor		O
antagonists		O
,		O
a		O
series		O
of		O
conformationally		O
restricted		O
analogues		O
of		O
histamine		O
with		O
a		O
chiral		B-MODIFIER
cis		B-PARTIUPAC
-		I-PARTIUPAC
or		O
trans		B-IUPAC
-		I-IUPAC
cyclopropane		I-IUPAC
structure		B-MODIFIER
were		O
designed		O
on		O
the		O
basis		O
of		O
this		O
strategy		O
.		O
It		O
revealed		O
marked		O
anxiolytic		O
-		O
like		O
activity		O
in		O
the		O
Vogel		O
test		O
in		O
rats		O
,		O
comparable		O
to		O
that		O
of		O
the		O
reference		O
drug		O
diazepam		O
,		O
and		O
exhibited		O
antidepressant		O
-		O
like		O
activity		O
in		O
the		O
Porsolt		O
test		O
in		O
rats		O
.		O
The		O
protected		O
derivatives		O
were		O
deblocked		O
using		O
standard		O
conditions		O
to		O
afford		O
the		O
desired		O
imidazo		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
-		I-IUPAC
isothiazole		I-IUPAC
nucleosides		B-MODIFIER
,		O
usually		O
as		O
crystalline		O
solids		O
.		O
sigma		O
receptor		O
affinities		O
ranged		O
from		O
1.34		O
nM		O
for		O
6,7		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
(		O
12		O
)		O
to		O
455		O
nM		O
for		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
[		O
(		O
-		O
)		O
-		O
4		O
]		O
.		O
Compounds		O
with		O
substituents		O
(		O
F		O
,		O
CF3		O
,		O
Me		O
)		O
in		O
the		O
5		O
-		O
or		O
6		O
-		O
position		O
of		O
the		O
isobenzofuran		O
exert		O
increased		O
affinity		O
for		O
sigma		O
1		O
binding		O
sites		O
(		O
IC50		O
(		O
sigma		O
1		O
)		O
=		O
5-30		O
nM		O
,		O
IC50		O
(		O
sigma		O
2		O
)		O
=		O
0.3-7		O
nM		O
)		O
,		O
thus		O
rendering		O
unselective		O
compounds		O
.		O
In		O
vitro		O
compounds		O
35		O
and		O
39		O
bound		O
to		O
[		O
3H		O
]		O
mepyramine		O
-		O
labeled		O
guinea		O
pig		O
cerebellar		O
membranes		O
with		O
a		O
pKi		O
of		O
6.1		O
and		O
5.9		O
,		O
respectively		O
.		O
Compound		O
17		O
was		O
unstable		O
in		O
tissue		O
culture		O
media		O
,		O
failed		O
to		O
achieve		O
nuclear		O
access		O
,		O
and		O
was		O
excluded		O
from		O
further		O
consideration		O
.		O
The		O
two		O
analogs		O
as		O
well		O
as		O
the		O
previously		O
reported		O
beta		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
and		O
beta		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
were		O
studied		O
as		O
growth		O
inhibitors		O
of		O
Escherichia		O
coli		O
9723		O
,		O
Leuconostoc		O
dextranicum		O
8086		O
,		O
and		O
Lactobacillus		O
plantarum		O
8014		O
.		O
The		O
synthesis		O
of		O
2'		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
propargyl		I-IUPAC
-		I-IUPAC
5,8		I-IUPAC
-		I-IUPAC
dideazafolic		I-IUPAC
acid		I-IUPAC
and		O
its		O
2		B-IUPAC
-		I-IUPAC
desamino		I-IUPAC
,		O
2		B-IUPAC
-		I-IUPAC
desamino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxymethyl		I-IUPAC
,		O
and		O
2		B-IUPAC
-		I-IUPAC
desamino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
analogues		B-MODIFIER
is		O
described		O
.		O
Antagonist		O
/		O
agonist		O
binding		O
ratios		O
were		O
not		O
obtained		O
for		O
transfected		O
m		O
(		O
3		O
)		O
-		O
receptors		O
,		O
since		O
significant		O
oxotremorine		O
-		O
M		O
binding		O
could		O
not		O
be		O
detected		O
.		O
Due		O
to		O
the		O
antiviral		O
activity		O
of		O
certain		O
5		O
-		O
substituted		O
imidazole		O
nucleosides		O
related		O
to		O
ribavirin		O
,		O
5		B-IUPAC
-		I-IUPAC
methylimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
nucleosides		B-MODIFIER
having		O
beta		B-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
,		O
2		B-PARTIUPAC
-		I-PARTIUPAC
deoxy		I-PARTIUPAC
-		I-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
and		O
-		B-PARTIUPAC
alpha		I-PARTIUPAC
-		I-PARTIUPAC
D		I-PARTIUPAC
-		I-PARTIUPAC
ribofuranosyl		I-PARTIUPAC
,		O
and		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
moieties		B-MODIFIER
have		O
been		O
prepared		O
and		O
tested		O
as		O
antiviral		O
agents		O
.		O
All		O
compounds		O
prepared		O
were		O
evaluated		O
for		O
their		O
ability		O
to		O
inhibit		O
leukemia		O
L1210		O
cell		O
proliferation		O
.		O
Also		O
included		O
in		O
the		O
study		O
were		O
3		B-PARTIUPAC
-		I-PARTIUPAC
oxo		I-PARTIUPAC
-		I-PARTIUPAC
3H		I-PARTIUPAC
-		I-PARTIUPAC
naphtho		I-PARTIUPAC
[		I-PARTIUPAC
2,1		I-PARTIUPAC
-		I-PARTIUPAC
b		I-PARTIUPAC
]		I-PARTIUPAC
pyran		I-PARTIUPAC
-		I-PARTIUPAC
1		I-PARTIUPAC
-		I-PARTIUPAC
acetic		I-PARTIUPAC
,		O
2		B-PARTIUPAC
-		I-PARTIUPAC
oxo		I-PARTIUPAC
-		I-PARTIUPAC
2H		I-PARTIUPAC
-		I-PARTIUPAC
naphtho		I-PARTIUPAC
[		I-PARTIUPAC
1,2		I-PARTIUPAC
-		I-PARTIUPAC
b		I-PARTIUPAC
]		I-PARTIUPAC
pyran		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
acetic		I-PARTIUPAC
,		O
and		O
1		B-IUPAC
-		I-IUPAC
naphthylacetic		I-IUPAC
acids		I-IUPAC
.		O
The		O
cytotoxicity		O
of		O
this		O
series		O
of		O
water		O
-		O
soluble		O
bis		B-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylazopyridine		I-IUPAC
)		I-IUPAC
complexes		B-MODIFIER
has		O
been		O
determined		O
in		O
A2780		O
human		O
ovarian		O
carcinoma		O
and		O
A2780cisR		O
,		O
the		O
corresponding		O
cisplatin		O
-		O
resistant		O
cell		O
line		O
.		O
It		O
is		O
expected		O
that		O
compound		O
55		O
may		O
be		O
used		O
as		O
a		O
potent		O
drug		O
with		O
few		O
side		O
effects		O
in		O
the		O
treatment		O
of		O
psychosis		O
.		O
These		O
results		O
suggest		O
that		O
the		O
receptor		O
binding		O
affinity		O
was		O
not		O
only		O
dependent		O
on		O
the		O
number		O
of		O
RGD		O
moieties		O
but		O
also		O
on		O
the		O
spatial		O
alignments		O
of		O
the		O
pendant		O
peptides		O
.		O
4beta		B-IUPAC
,		I-IUPAC
19		I-IUPAC
-		I-IUPAC
Diol		I-IUPAC
27		O
,		O
previously		O
synthesized		O
,		O
was		O
identified		O
as		O
an		O
extremely		O
powerful		O
competitive		O
inhibitor		O
of		O
aromatase		O
(		O
K		O
(		O
i		O
)		O
=		O
3.4		O
nM		O
)		O
.		O
Additional		O
bioassay		O
data		O
for		O
these		O
compounds		O
are		O
also		O
reported		O
.		O
Pyrimido		B-IUPAC
[		I-IUPAC
5,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
analogues		B-MODIFIER
bearing		O
bulky		O
,		O
weakly		O
basic		O
solubilizing		O
side		O
chains		O
linked		O
to		O
the		O
6		O
-		O
position		O
through		O
a		O
secondary		O
amine		O
generally		O
retained		O
potency		O
both		O
against		O
the		O
isolated		O
enzyme		O
and		O
for		O
inhibition		O
of		O
autophosphorylation		O
of		O
EGFR		O
in		O
intact		O
A431		O
cells		O
.		O
Two		O
3		B-IUPAC
-		I-IUPAC
carboxythiophene		I-IUPAC
3		I-IUPAC
-		I-IUPAC
trifluoromethylbenzyl		I-IUPAC
esters		I-IUPAC
,		O
3d		O
(		O
49%		O
)		O
and		O
3f		O
(		O
63%		O
)		O
,		O
had		O
substantial		O
AE		O
activity		O
.		O
These		O
results		O
add		O
to		O
our		O
earlier		O
study		O
where		O
we		O
restrained		O
1		O
using		O
simple		O
monocyclic		O
heterocycles		O
.		O
A		O
series		O
of		O
5		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
was		O
evaluated		O
for		O
anticonvulsant		O
activity		O
.		O
All		O
of		O
these		O
derivatives		O
retain		O
substantial		O
affinity		O
for		O
the		O
mu		O
opioid		O
receptor		O
.		O
The		O
ring		B-MODIFIER
-		I-MODIFIER
saturated		I-MODIFIER
analogue		I-MODIFIER
2		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
morpholino		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
(		I-IUPAC
6'		I-IUPAC
,		I-IUPAC
7'		I-IUPAC
,		I-IUPAC
8'		I-IUPAC
,		I-IUPAC
9'		I-IUPAC
-		I-IUPAC
tetrahydrodibenzothiophene		I-IUPAC
)		I-IUPAC
chromen		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
,		O
36		O
,		O
retained		O
potent		O
activity		O
(		O
IC50		O
vs		O
DNA		O
-		O
PK		O
=		O
23		O
nM		O
)		O
.		O
DPEAP		O
(		O
2		O
)		O
and		O
related		O
compounds		O
provide		O
new		O
leads		O
for		O
the		O
development		O
of		O
antagonists		O
for		O
the		O
human		O
A		O
(		O
3		O
)		O
AR		O
.		O
In		O
the		O
binding		O
assay		O
,		O
the		O
relative		O
order		O
of		O
potencies		O
for		O
the		O
analogues		O
in		O
the		O
5alpha		O
-		O
and		O
5beta		O
-		O
series		O
is		O
identical		O
.		O
Furthermore		O
,		O
it		O
antagonized		O
in		O
vivo		O
seizures		O
induced		O
by		O
icv		O
administration		O
of		O
AMPA		O
or		O
kainate		O
(		O
KA		O
)		O
.		O
Diazotization		O
of		O
8		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
methano		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzazocine		I-IUPAC
(		O
2		O
)		O
followed		O
by		O
the		O
reaction		O
with		O
CH3SNa		O
afforded		O
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
methylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4,5,6		I-IUPAC
-		I-IUPAC
hexahydro		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
methano		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzazocine		I-IUPAC
(		O
3		O
)		O
.		O
Spontaneous		O
elimination		O
of		O
acrolein		O
from		O
3a		O
would		O
then		O
generate		O
the		O
free		O
nucleotide		O
,		O
FdUMP		O
.		O
Finally		O
,		O
there		O
was		O
no		O
correlation		O
between		O
the		O
SAR		O
for		O
the		O
human		O
MDR1		O
Pgp		O
inhibition		O
and		O
the		O
SAR		O
for		O
Saccharomyces		O
cerevisiae		O
antifungal		O
activity		O
,		O
which		O
is		O
mediated		O
by		O
an		O
inositol		O
phosphoceramide		O
synthase		O
activity		O
.		O
When		O
compounds		O
were		O
intraduodenally		O
administered		O
to		O
the		O
guinea		O
pig		O
,		O
1		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2'		I-PARTIUPAC
-		I-PARTIUPAC
ethoxyethyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
,		O
1		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
methoxypropyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
,		O
1		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3'		I-PARTIUPAC
-		I-PARTIUPAC
butenyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
propylxanthines		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
oxopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
propylxanthine		I-IUPAC
,		O
and		O
denbufylline		O
(		O
1,3		B-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
oxopropyl		I-IUPAC
)		I-IUPAC
xanthine		I-IUPAC
)		O
effectively		O
inhibited		O
the		O
acetylcholine		O
-		O
induced		O
bronchospasm		O
without		O
heart		O
stimulation		O
or		O
central		O
nervous		O
system		O
-		O
stimulation		O
at		O
the		O
effective		O
dosage		O
range		O
.		O
Excellent		O
in		O
vivo		O
activity		O
in		O
the		O
trypanosomal		O
STIB900		O
mouse		O
model		O
was		O
found		O
for		O
five		O
of		O
the		O
diamidines		O
on		O
ip		O
dosage		O
;		O
these		O
compounds		O
gave		O
4/4		O
cures		O
in		O
this		O
model		O
.		O
Compounds		O
14		O
,		O
15		O
,		O
18		O
,		O
19		O
,		O
and		O
21		O
,		O
mostly		O
3'		B-IUPAC
-		I-IUPAC
chlorophenylpiperazine		I-IUPAC
derivatives		B-MODIFIER
,		O
can		O
be		O
classified		O
as		O
mixed		O
5		O
-		O
HT		O
(		O
1A		O
)		O
/		O
5		O
-		O
HT		O
(		O
2A		O
)		O
/		O
alpha		O
(		O
1		O
)		O
ligands		O
.		O
The		O
remaining		O
target		O
compounds		O
were		O
produced		O
by		O
alkylation		O
of		O
lidocaine		O
or		O
of		O
2		B-IUPAC
-		I-IUPAC
phthalimidoaceto		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
6'		I-IUPAC
-		I-IUPAC
xylidide		I-IUPAC
with		O
the		O
appropriate		O
halide		O
and		O
sodium		O
hydride		O
,		O
followed		O
by		O
hydrazinolysis		O
where		O
necessary		O
.		O
All		O
had		O
retained		O
or		O
improved		O
activity		O
against		O
both		O
the		O
L1210		O
:		O
R7A		O
and		O
L1210		O
:		O
1565		O
cell		O
lines		O
.		O
On		O
the		O
other		O
hand		O
,		O
the		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylhydroxypropynyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
Ado		O
(		O
9e		O
,		O
EC		O
(		O
50		O
)		O
(		O
A		O
(		O
2B		O
)		O
)		O
=		O
0.73		O
microM		O
)		O
showed		O
a		O
significantly		O
increase		O
of		O
potency		O
at		O
the		O
A		O
(		O
2B		O
)		O
subtype		O
in		O
comparison		O
with		O
the		O
N		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
,		O
and		O
the		O
unsubstituted		O
adenosine		O
derivatives		O
,		O
although		O
it		O
resulted		O
in		O
being		O
less		O
potent		O
than		O
(		O
S		O
)		O
-		O
PHPNECA		O
(		O
1e		O
,		O
EC		O
(		O
50		O
)		O
(		O
A		O
(		O
2B		O
)		O
)		O
=		O
0.22		O
microM		O
)		O
.		O
Other		O
linkers		O
between		O
the		O
naphthalene		O
and		O
2,4		B-IUPAC
-		I-IUPAC
thiazolidinedione		I-IUPAC
rings		B-MODIFIER
,		O
such		O
as		O
thio		O
,		O
methylene		O
,		O
oxy		O
,		O
and		O
sulfinyl		O
led		O
to		O
decreased		O
antihyperglycemic		O
activity		O
.		O
Heteroarotinoids		O
8		O
and		O
12-17		O
had		O
ID50		O
values		O
of		O
35		O
nmol		O
or		O
greater		O
.		O
A		O
number		O
of		O
nitrogen		O
analogues		O
of		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
guanine		I-IUPAC
[		O
acylovir		O
,		O
Zovirax		O
]		O
containing		O
amine		O
functions		O
in		O
the		O
side		O
chain		O
were		O
synthesized		O
and		O
tested		O
for		O
antiviral		O
activity		O
.		O
4,5		O
-		O
Diphenyl		O
-		O
2		O
-		O
oxazolenonanoic		O
acid		O
(		O
2		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
diphenyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxazolyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
phenoxy		I-IUPAC
]		I-IUPAC
acetic		I-IUPAC
acid		I-IUPAC
(		O
3		O
)		O
were		O
previously		O
identified		O
as		O
nonprostanoid		O
prostacyclin		O
(		O
PGI2		O
)		O
mimetics		O
that		O
inhibit		O
ADP		O
-		O
induced		O
aggregation		O
of		O
human		O
platelets		O
in		O
vitro		O
.		O
Selective		O
condensation		O
of		O
5		O
with		O
2		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
substituted		B-MODIFIER
-		O
phenyl		B-IUPAC
)		I-IUPAC
piperazin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
ethylamine		I-IUPAC
gave		O
the		O
2		B-IUPAC
-		I-IUPAC
arylpiperazinylethylamino		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
derivatives		B-MODIFIER
6a		O
-		O
c		O
,		O
which		O
were		O
investigated		O
in		O
binding		O
studies		O
toward		O
the		O
three		O
alpha1		O
-		O
adrenergic		O
and		O
5		O
-		O
HT1A		O
-		O
serotonergic		O
receptor		O
subtypes		O
.		O
The		O
major		O
product		O
of		O
conjugation		O
had		O
the		O
opposite		O
stereochemistry		O
at		O
the		O
benzylic		O
carbon		O
,		O
indicating		O
that		O
the		O
reaction		O
proceeded		O
primarily		O
with		O
inversion		O
of		O
configuration		O
.		O
Phototoxic		O
liability		O
precluded		O
clinical		O
evaluation		O
of		O
a		O
member		O
of		O
the		O
series		O
.		O
Crystal		O
structure		O
determinations		O
have		O
been		O
carried		O
out		O
for		O
the		O
following		O
seven		O
thyrotropin		O
releasing		O
hormone		O
analogues		O
:		O
I		O
,		O
(		B-IUPAC
3R		I-IUPAC
,		I-IUPAC
6R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
oxothiomorpholin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylcarbonyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
histidinyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
proline		I-IUPAC
amide		I-IUPAC
;		O
II		O
,		O
(		B-IUPAC
3R		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
oxothiomorpholin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylcarbonyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
histid		I-IUPAC
inyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
proline		I-IUPAC
amide		I-IUPAC
;		O
III		O
,		O
(		B-IUPAC
4R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxothiazolidin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ylcarbonyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
histidinyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
prol		I-IUPAC
ine		I-IUPAC
amide		I-IUPAC
;		O
IV		O
,		O
5		B-IUPAC
-		I-IUPAC
ethylorotyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
histidinyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
proline		I-IUPAC
amide		I-IUPAC
;		O
V		O
,		O
5		B-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylorotyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
histidinyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
proline		I-IUPAC
amide		I-IUPAC
;		O
VI		O
,		O
5		B-IUPAC
-		I-IUPAC
bromoorotyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
histidinyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
proline		I-IUPAC
amide		I-IUPAC
;		O
and		O
VII		O
,		O
Phe2		O
-		O
TRH		O
.		O
The		O
results		O
obtained		O
with		O
different		O
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
sulfamoylbenzoic		I-IUPAC
acids		I-IUPAC
supported		O
the		O
earlier		O
concept		O
regarding		O
the		O
steric		O
influence		O
of		O
the		O
4		O
-		O
substituent		O
on		O
the		O
diuretic		O
potency		O
of		O
sulfamoylbenzoic		O
acid		O
diuretics		O
.		O
Marked		O
inhibition		O
of		O
tetrabenazine		O
-		O
induced		O
ptosis		O
is		O
a		O
property		O
of		O
most		O
antidepressants		O
,		O
and		O
significant		O
antitetrabenazine		O
activity		O
is		O
observed		O
for		O
several		O
of		O
these		O
compounds		O
.		O
A		O
series		O
of		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
naphthalenylsulfonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
thiazolidinediones		I-IUPAC
were		O
synthesized		O
and		O
evaluated		O
for		O
antihyperglycemic		O
activity		O
in		O
an		O
insulin		O
-		O
resistant		O
,		O
genetically		O
diabetic		O
db		O
/		O
db		O
mouse		O
model		O
of		O
non		O
-		O
insulin		O
-		O
dependent		O
diabetes		O
mellitus		O
(		O
NIDDM		O
)		O
.		O
Location		O
of		O
the		O
fluorine		O
atom		O
at		O
the		O
C		O
-		O
4		O
position		O
of		O
the		O
piperidine		O
ring		O
was		O
the		O
most		O
favorable		O
,		O
and		O
among		O
the		O
various		O
substituents		O
tested		O
,		O
the		O
ability		O
of		O
the		O
fluorine		O
was		O
unique		O
in		O
improving		O
the		O
oral		O
activity		O
of		O
this		O
family		O
of		O
ligands		O
.		O
N		B-IUPAC
-		I-IUPAC
Acetyl		I-IUPAC
derivatives		B-MODIFIER
showed		O
irreversible		O
inactivation		O
vis		O
-		O
a		O
-		O
vis		O
subtilisin		O
,		O
while		O
the		O
N		B-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
ones		I-IUPAC
were		O
specific		O
toward		O
chymotrypsin		O
.		O
The		O
9		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
analogue		B-MODIFIER
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
demethoxydaunomycin		I-IUPAC
has		O
been		O
synthesized		O
from		O
2,5		B-IUPAC
-		I-IUPAC
dimethoxybenzaldehyde		I-IUPAC
.		O
gamma		O
-		O
CyanoMTX		O
may		O
be		O
viewed		O
as		O
a		O
congener		O
of		O
the		O
nonpolyglutamated		O
MTX		O
analogue		O
gamma		O
-		O
fluoroMTX		O
.		O
Incorporation		O
of		O
a		O
fluorine		O
atom		O
in		O
the		O
beta		O
-		O
position		O
to		O
the		O
amino		O
function		O
in		O
the		O
side		O
chain		O
led		O
to		O
analogues		O
that		O
exhibited		O
,		O
in		O
general		O
,		O
enhanced		O
and		O
long		O
-		O
lasting		O
5		O
-		O
HT1A		O
agonist		O
activity		O
in		O
rats		O
after		O
oral		O
administration		O
.		O
Pirenzepine		O
displayed		O
a		O
higher		O
potency		O
than		O
II		O
for		O
inhibition		O
of		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
l		I-IUPAC
-		I-IUPAC
quinuclidinyl		I-IUPAC
benzilate		I-IUPAC
(		O
[		O
3H		O
]		O
-		O
l		O
-		O
QNB		O
)		O
binding		O
to		O
rat		O
brain		O
sections		O
.		O
However		O
,		O
there		O
was		O
only		O
modest		O
separation		O
between		O
activity		O
against		O
HCMV		O
and		O
cytotoxicity		O
and		O
there		O
was		O
virtually		O
no		O
selectivity		O
for		O
activity		O
against		O
HSV		O
-		O
1		O
.		O
The		O
compounds		O
were		O
prepared		O
by		O
two		O
methods		O
:		O
(		O
1		O
)		O
direct		O
alkylation		O
of		O
adenosine		O
with		O
an		O
appropriately		O
substituted		O
benzyl		O
bromide		O
to		O
give		O
the		O
N1		O
-		O
substituted		O
derivative		O
which		O
was		O
then		O
rearranged		O
in		O
base		O
to		O
give		O
the		O
N6		O
-		O
substituted		O
compound		O
,		O
and		O
(		O
2		O
)		O
by		O
nucleophilic		O
displacement		O
of		O
chlorine		O
in		O
6		B-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
ribonucleoside		B-MODIFIER
,		O
6		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminopurine		I-IUPAC
ribonucleoside		B-MODIFIER
,		O
and		O
6		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminopurine		I-IUPAC
with		O
an		O
amine		O
.		O
Compounds		O
9-13		O
and		O
15		O
were		O
shown		O
to		O
be		O
essentially		O
inactive		O
against		O
isoniazide		O
-		O
induced		O
convulsions		O
in		O
mice		O
after		O
subcutaneous		O
administration		O
.		O
More		O
convenient		O
one		O
-		O
pot		O
alkylation		O
-		O
elimination		O
of		O
adenine		O
(		O
18		O
)		O
or		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
30		O
)		O
with		O
24		O
+		O
25		O
afforded		O
(		B-PARTIUPAC
Z		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methylenecyclopropane		I-IUPAC
derivatives		B-MODIFIER
26		O
+		O
27		O
and		O
31		O
+		O
32		O
.		O
Of		O
the		O
newly		O
synthesized		O
compounds		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
cyanamido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
6		O
)		O
exhibited		O
the		O
most		O
potent		O
anti		O
-		O
HSV		O
-		O
1		O
activity		O
,		O
which		O
was		O
equipotent		O
to		O
acyclovir		O
and		O
superior		O
to		O
5		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
EDU		O
)		O
.		O
These		O
compounds		O
were		O
also		O
found		O
to		O
bind		O
to		O
site		O
II		O
of		O
human		O
serum		O
albumin		O
(		O
HSA		O
)		O
.		O
Synadenol		O
(		O
14		O
)		O
and		O
the		O
E		O
-		O
isomer		O
(		O
16		O
)		O
were		O
substrates		O
of		O
moderate		O
efficiency		O
for		O
adenosine		O
deaminase		O
from		O
calf		O
intestine		O
.		O
However		O
,		O
(		O
-		O
)		O
-		O
2		O
also		O
showed		O
moderate		O
affinity		O
for		O
sigma		O
receptors		O
,		O
with		O
a		O
Ki		O
of		O
594		O
+		O
/		O
-		O
3		O
nM		O
[		O
[		O
3H		O
]		O
-		O
(		O
+		O
)		O
-		O
3		O
-		O
PPP		O
]		O
.		O
On		O
the		O
whole		O
,		O
(		O
FMS		O
)		O
(		O
3		O
)		O
(		O
-		O
)		O
insulin		O
represents		O
a		O
prototype		O
version		O
of		O
a		O
water		O
-		O
soluble		O
,		O
long		O
-		O
acting		O
preparation		O
of		O
insulin		O
.		O
This		O
also		O
implies		O
,		O
therefore		O
,		O
that		O
the		O
hallucinogenic		O
phenethylamines		O
cannot		O
be		O
directly		O
superimposed		O
on		O
LSD		O
in		O
a		O
common		O
binding		O
orientation		O
for		O
these		O
two		O
chemical		O
classes		O
,		O
contrary		O
to		O
previous		O
hypotheses		O
.		O
Phosphorylation		O
of		O
unprotected		O
4		O
with		O
POCl3		O
and		O
subsequent		O
debenzylation		O
of		O
the		O
intermediate		O
17		O
gave		O
pyrazofurin		B-IUPAC
5'		I-IUPAC
-		I-IUPAC
phosphate		I-IUPAC
(		O
18		O
)		O
,		O
which		O
provided		O
the		O
first		O
chemical		O
synthesis		O
of		O
18		O
.		O
The		O
(		B-IUPAC
glycolato		I-IUPAC
)		I-IUPAC
-		I-IUPAC
platinum		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
complexes		B-MODIFIER
were		O
highly		O
cytotoxic		O
toward		O
four		O
human		O
stomach		O
cancer		O
cell		O
lines		O
,		O
SNU		O
-		O
1		O
,		O
SNU		O
-		O
5		O
,		O
SNU		O
-		O
16		O
,		O
and		O
NCI		O
-		O
N87		O
,		O
and		O
among		O
them		O
,		O
complexes		O
3d		O
-		O
g		O
were		O
even		O
more		O
cytotoxic		O
than		O
cisplatin		O
.		O
Functionally		O
,		O
the		O
stereoisomers		O
displayed		O
a		O
similar		O
alpha		O
(		O
1		O
)		O
-		O
selectivity		O
profile		O
,		O
that		O
is		O
alpha		O
(		O
1D		O
)		O
&		O
gt		O
;		O
alpha		O
(		O
1B		O
)		O
&		O
gt		O
;		O
alpha		O
(		O
1A		O
)		O
,		O
which		O
is		O
different		O
from		O
that		O
exhibited		O
by		O
the		O
reference		O
compound		O
1		O
.		O
The		O
lead		O
compound		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluoylethynyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
effectively		O
inhibited		O
thymidylate		O
synthetase		O
.		O
A		O
series		O
of		O
esters		O
of		O
6beta		B-IUPAC
-		I-IUPAC
hydroxynortropane		I-IUPAC
and		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
analogue		B-MODIFIER
6beta		B-IUPAC
-		I-IUPAC
tropanol		I-IUPAC
were		O
synthesized		O
and		O
screened		O
versus		O
binding		O
of		O
an		O
antagonist		O
(		O
quinuclidinyl		B-IUPAC
benzilate		I-IUPAC
)		O
and		O
an		O
agonist		O
(		O
oxotremorine		O
-		O
M		O
)		O
at		O
sites		O
on		O
human		O
m		O
(		O
1		O
)		O
-		O
,		O
m		O
(		O
2		O
)		O
-		O
,		O
m		O
(		O
3		O
)		O
-		O
,		O
and		O
m		O
(		O
4		O
)		O
-		O
muscarinic		O
receptors		O
in		O
transfected		O
cell		O
membranes		O
and		O
on		O
native		O
M		O
(		O
1		O
)		O
-		O
muscarinic		O
receptors		O
in		O
rat		O
brain		O
membranes		O
and		O
native		O
M		O
(		O
2		O
)		O
-		O
muscarinic		O
receptors		O
in		O
rat		O
heart		O
membranes		O
.		O
The		O
various		O
C11		O
-		O
substituents		O
were		O
introduced		O
using		O
efficient		O
nickel		O
-		O
and		O
palladium		O
-		O
catalyzed		O
reactions		O
of		O
the		O
corresponding		O
triflate		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
sulfonyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
aporphine		I-IUPAC
(		O
6		O
)		O
.		O
Among		O
these		O
tyrosine		O
analogues		O
were		O
the		O
bicyclic		O
structures		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxyisoquinoline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
HO		O
-		O
Tic		O
)		O
,		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxytetralin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
Hat		O
)		O
,		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxyindan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
Hai		O
)		O
in		O
which		O
rotations		O
about		O
the		O
C		O
alpha		O
-		O
C		O
beta		O
and		O
C		O
beta		O
-		O
C		O
gamma		O
bonds		O
are		O
restricted		O
due		O
to		O
cyclization		O
of		O
the		O
side		O
chain		O
to		O
the		O
backbone		O
.		O
Incubation		O
of		O
1		O
and		O
glutathione		O
under		O
the		O
same		O
experimental		O
conditions		O
yields		O
the		O
(		B-MODIFIER
2R		I-MODIFIER
,		I-MODIFIER
4R		I-MODIFIER
)		I-MODIFIER
-		I-MODIFIER
and		O
(		B-MODIFIER
2S		I-MODIFIER
,		I-MODIFIER
4R		I-MODIFIER
)		I-MODIFIER
-		I-MODIFIER
epimers		I-MODIFIER
of		O
alpha		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
carboxymethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
delta		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
thiazolidinepentanoic		I-IUPAC
acid		I-IUPAC
.		O
Among		O
the		O
resolved		O
analogs		O
tested		O
,		O
the		O
activity		O
was		O
found		O
to		O
reside		O
exclusively		O
in		O
the		O
(		O
3aS		O
)		O
-		O
(		O
-		O
)		O
-		O
enantiomers		O
.		O
A		O
structural		O
isomer		O
of		O
2		B-IUPAC
,		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
3,1,2		I-IUPAC
-		I-IUPAC
benzoxazaphosphorin		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
(		O
3		O
)		O
,		O
and		O
cognate		O
systems		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
1,3,2		I-IUPAC
-		I-IUPAC
benzodiazaphosphorin		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
(		O
4		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
1,3,2		I-IUPAC
-		I-IUPAC
benzodioxaphosphorin		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
(		O
5		O
)		O
were		O
also		O
prepared		O
for		O
comparative		O
purposes		O
.		O
Both		O
12a		O
and		O
its		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		O
substituted		B-MODIFIER
analogue		B-MODIFIER
12b		O
were		O
converted		O
to		O
versatile		O
6		B-IUPAC
-		I-IUPAC
bromomethyl		I-IUPAC
intermediates		B-MODIFIER
13a		O
and		O
13b		O
from		O
which		O
important		O
antifolates		O
may		O
be		O
readily		O
derived		O
.		O
These		O
compounds		O
showed		O
significant		O
inhibitory		O
action		O
against		O
isonicotinic		O
acid		O
hydrazide		O
and		O
streptomycin		O
-		O
resistant		O
strains		O
of		O
M		O
.		O
The		O
CoMFA		O
models		O
with		O
steric		O
and		O
electrostatic		O
fields		O
exhibited		O
r		O
(		O
2		O
)		O
(		O
cv		O
)		O
0.452-0.722		O
,		O
r		O
(		O
2		O
)		O
(		O
ncv		O
)		O
0.812-0.986		O
,		O
r		O
(		O
2		O
)		O
(		O
pred		O
)		O
0.597-0.870		O
,		O
whereas		O
CoMFA		O
ClogP		O
models		O
showed		O
r		O
(		O
2		O
)		O
(		O
cv		O
)		O
0.420-0.707		O
,		O
r		O
(		O
2		O
)		O
(		O
ncv		O
)		O
0.849-0.957		O
,		O
r		O
(		O
2		O
)		O
(		O
pred		O
)		O
0.600-0.870		O
.		O
MIH		O
possessed		O
a		O
maleimide		O
group		O
for		O
mAb		O
conjugation		O
and		O
a		O
butylstannyl		O
moiety		O
for		O
high		O
-		O
yield		O
and		O
site		O
-		O
specific		O
radioiodination		O
,		O
and		O
the		O
two		O
functional		O
groups		O
were		O
linked		O
via		O
an		O
ester		O
bond		O
to		O
release		O
m		B-IUPAC
-		I-IUPAC
iodohippuric		I-IUPAC
acid		I-IUPAC
.		O
In		O
contrast		O
,		O
three		O
compounds		O
,		O
17c		O
,		O
24		O
,		O
and		O
26		O
,		O
displayed		O
moderate		O
to		O
high		O
affinity		O
for		O
[		O
(		O
3		O
)		O
H		O
]		O
cytisine		O
binding		O
sites		O
,		O
while		O
three		O
(		O
17b		O
,		O
18b		O
,		O
c		O
)		O
and		O
six		O
(		O
17a		O
,		O
d		O
,		O
e		O
and		O
18a		O
,		O
d		O
,		O
e		O
)		O
compounds		O
showed		O
weak		O
and		O
poor		O
affinity		O
,		O
respectively		O
,		O
for		O
these		O
same		O
sites		O
.		O
Further		O
derivatizations		O
provided		O
an		O
additional		O
group		O
of		O
pyrido		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
nucleosides		B-MODIFIER
.		O
Sulfonation		O
of		O
1,4		B-IUPAC
-		I-IUPAC
dimethylisoquinoline		I-IUPAC
,		O
followed		O
by		O
reaction		O
with		O
potassium		O
hydroxide		O
,		O
acetylation		O
,		O
and		O
oxidation		O
,		O
gave		O
5		B-IUPAC
-		I-IUPAC
acetoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylisoquinoline		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
carboxaldehyde		I-IUPAC
(		O
40		O
)		O
.		O
The		O
analogue		O
[		O
CalphaMe		O
-		O
Leu27		O
,		O
DHis32		O
]		O
astressin		O
(		O
16		O
)		O
was		O
more		O
potent		O
(		O
although		O
not		O
statistically		O
in		O
all		O
cases		O
)		O
than		O
the		O
other		O
four		O
analogues		O
in		O
vitro		O
.		O
However		O
,		O
a		O
selective		O
inhibition		O
to		O
the		O
cancer		O
cells		O
was		O
observed		O
for		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
xylofuranosyl		I-IUPAC
)		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
2b		O
)		O
,		O
which		O
is		O
a		O
potent		O
inhibitor		O
of		O
HTB		O
-		O
81		O
(		O
EC		O
(		O
50		O
)		O
:		O
0.73		O
microM		O
)		O
and		O
has		O
a		O
favorable		O
in		O
vitro		O
selectivity		O
index		O
(		O
28		O
)		O
.		O
In		O
general		O
,		O
3alpha		B-IUPAC
-		I-IUPAC
(		I-IUPAC
diphenylmethoxy		I-IUPAC
)		I-IUPAC
tropane		I-IUPAC
(		O
benztropine		O
)		O
-		O
based		O
dopamine		O
uptake		O
inhibitors		O
do		O
not		O
demonstrate		O
cocaine		O
-		O
like		O
pharmacological		O
activity		O
in		O
models		O
of		O
psychostimulant		O
abuse		O
and		O
have		O
been		O
proposed		O
as		O
potential		O
medications		O
for		O
the		O
treatment		O
of		O
cocaine		O
addiction		O
.		O
Variable		O
-		O
temperature		O
proton		O
nuclear		O
magnetic		O
resonance		O
studies		O
have		O
shown		O
that		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propylidene		I-IUPAC
)		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylpiperazino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
a		I-IUPAC
,		I-IUPAC
d		I-IUPAC
]		I-IUPAC
cycloheptene		I-IUPAC
,		O
a		O
5,11		B-IUPAC
-		I-IUPAC
dicarbo		I-IUPAC
analogue		B-MODIFIER
of		O
the		O
atypical		O
neuroleptic		O
agent		O
clozapine		B-IUPAC
[		I-IUPAC
8		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylpiperazino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
,		I-IUPAC
e		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,4		I-IUPAC
]		I-IUPAC
diazepine		I-IUPAC
]		I-IUPAC
,		O
exists		O
as		O
thermally		O
stable		O
configurational		O
isomers		O
.		O
In		O
monkeys		O
,		O
23		O
showed		O
no		O
morphine		O
-		O
like		O
physical		O
dependence		O
liability		O
,		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidinol		I-IUPAC
esters		I-IUPAC
24		O
and		O
25		O
showed		O
no		O
binding		O
to		O
the		O
opiate		O
receptor		O
in		O
rat		O
brain		O
homogenates		O
.		O
Biodistribution		O
results		O
of		O
[		O
125I		O
]		O
-		O
10		O
in		O
mice		O
indicate		O
that		O
compound		O
10		O
is		O
readily		O
metabolized		O
via		O
deiodination		O
in		O
vivo		O
,		O
possibly		O
by		O
serving		O
as		O
a		O
substrate		O
for		O
the		O
enzyme		O
S		B-IUPAC
-		I-IUPAC
adenosyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
homocysteine		I-IUPAC
hydrolase		O
.		O
A		O
series		O
of		O
4		B-IUPAC
-		I-IUPAC
phenylisoquinolone		I-IUPAC
derivatives		B-MODIFIER
were		O
synthesized		O
and		O
evaluated		O
for		O
NK1		O
(		O
substance		O
P		O
)		O
antagonist		O
activity		O
.		O
2,4		B-IUPAC
-		I-IUPAC
Diamino		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxyphenyl		I-IUPAC
)		I-IUPAC
ethynylbenzyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
28		O
)		O
,		O
with		O
an		O
IC		O
(		O
50		O
)		O
of		O
23		O
nM		O
and		O
an		O
SI		O
of		O
28		O
in		O
the		O
Pc		O
DHFR		O
assay		O
,		O
had		O
about		O
the		O
same		O
potency		O
as		O
PTX		O
and		O
was		O
520		O
times		O
more		O
potent		O
than		O
TMP		O
.		O
Compound		O
10		O
is		O
inactive		O
in		O
both		O
test		O
systems		O
.		O
The		O
predicted		O
binding		O
model		O
for		O
ILV		O
is		O
the		O
same		O
as		O
that		O
obtained		O
in		O
a		O
previous		O
docking		O
study		O
using		O
a		O
Monte		O
Carlo		O
method		O
and		O
is		O
consistent		O
with		O
the		O
structure		O
-		O
activity		O
relationships		O
for		O
this		O
class		O
of		O
ligands		O
.		O
A		O
number		O
of		O
5		B-IUPAC
-		I-IUPAC
heteroaromatic		I-IUPAC
-		O
substituted		B-MODIFIER
2'		B-IUPAC
-		I-IUPAC
deoxyuridines		I-IUPAC
were		O
synthesized		O
from		O
5		B-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
using		O
tetraorganotin		O
reagents		O
and		O
palladium		O
complexes		O
as		O
catalyst		O
.		O
The		O
antimicrobial		O
and		O
cytotoxic		O
properties		O
of		O
a		O
series		O
of		O
9,10		B-IUPAC
-		I-IUPAC
dihydrophenanthrenes		I-IUPAC
structurally		O
related		O
to		O
juncusol		O
(		O
1a		O
)		O
,		O
a		O
postulated		O
phytoalexin		O
with		O
confirmed		O
cytotoxic		O
properties		O
,		O
are		O
detailed		O
.		O
We		O
have		O
developed		O
a		O
generally		O
applicable		O
,		O
convenient		O
stepwise		O
solid		O
-		O
phase		O
synthetic		O
protocol		O
for		O
octreotide		O
(		O
D		O
-		O
Phe		O
-		O
Cys		O
-		O
Phe		O
-		O
D		O
-		O
Trp		O
-		O
Lys		O
-		O
Thr		O
-		O
Cys		O
-		O
threoninol		O
)		O
.		O
The		O
ultimate		O
activity		O
kinetic		O
assay		O
(		O
Daniels		O
,		O
S		O
.		O
Most		O
of		O
the		O
benzimidazoles		O
showed		O
high		O
affinity		O
for		O
the		O
AII		O
receptor		O
(		O
IC50		O
value		O
,		O
10		O
(		O
-		O
6		O
)		O
-		O
10		O
(		O
-		O
7		O
)		O
M		O
)		O
and		O
inhibited		O
the		O
AII		O
-		O
induced		O
pressor		O
response		O
at		O
1		O
or		O
3		O
mg		O
/		O
kg		O
po		O
,		O
and		O
the		O
effects		O
were		O
more		O
potent		O
than		O
those		O
of		O
CV		O
-		O
11194		O
and		O
DuP		O
753		O
.		O
Important		O
hydrogen		O
-		O
bonding		O
and		O
hydrophobic		O
interactions		O
with		O
the		O
protein		O
have		O
been		O
identified		O
for		O
this		O
inhibitor		O
.		O
In		O
addition		O
to		O
their		O
5		O
alpha		O
-		O
reductase		O
activities		O
,		O
17		B-IUPAC
beta		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
alkylformamides		I-IUPAC
)		I-IUPAC
were		O
also		O
studied		O
for		O
their		O
inhibitory		O
activities		O
on		O
dihydrotestosterone		O
(		O
DHT		O
)		O
-		O
stimulated		O
proliferation		O
of		O
androgen		O
-		O
sensitive		O
Shionogi		O
mouse		O
mammary		O
carcinoma		O
cells		O
(		O
clone		O
SEM		O
-		O
107		O
)		O
.		O
Compound		O
4d		O
had		O
affinities		O
of		O
12-33		O
nM		O
at		O
all		O
of		O
the		O
muscarinic		O
sites		O
,		O
with		O
4b		O
,		O
e		O
having		O
much		O
lower		O
affinity		O
.		O
A		O
conjugate		O
of		O
Boc		O
-		O
gamma		O
-		O
aminobutyric		O
acid		O
was		O
also		O
prepared		O
but		O
was		O
nonselective		O
.		O
N		O
-		O
Alkyl		O
derivatives		O
of		O
dexoxadrol		O
were		O
found		O
to		O
be		O
inactive		O
,		O
as		O
were		O
those		O
analogues		O
where		O
the		O
dioxolane		O
ring		O
was		O
modified		O
.		O
The		O
combined		O
results		O
from		O
these		O
systematic		O
studies		O
allowed		O
for		O
an		O
analysis		O
of		O
structural		O
features		O
in		O
the		O
native		O
peptide		O
that		O
are		O
important		O
for		O
receptor		O
activation		O
.		O
Condensation		O
of		O
4		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylisoquinoline		I-IUPAC
(		O
4		O
)		O
with		O
ammonium		O
hydroxide		O
,		O
methylamine		O
,		O
ethylamine		O
,		O
and		O
N		B-IUPAC
-		I-IUPAC
acetylethylenediamine		I-IUPAC
gave		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
,		O
4		B-IUPAC
-		I-IUPAC
methylamino		I-IUPAC
,		O
4		B-IUPAC
-		I-IUPAC
ethylamino		I-IUPAC
,		O
and		O
4		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
acetylethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
derivatives		B-MODIFIER
,		O
which		O
were		O
then		O
converted		O
to		O
amides		O
and		O
subsequently		O
oxidized		O
to		O
aldehydes		O
followed		O
by		O
condensation		O
with		O
thiosemicarbazide		O
to		O
yield		O
thiosemicarbazones		O
8a		O
-		O
c		O
,		O
9a		O
-		O
c		O
,		O
and		O
16		O
.		O
Other		O
tetramethyl		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyrrolinecarboxamide		I-IUPAC
compounds		B-MODIFIER
were		O
synthesized		O
by		O
acylating		O
the		O
aminoalkyl		B-IUPAC
compounds		B-MODIFIER
with		O
2,2,6,6		B-IUPAC
-		I-IUPAC
tetramethyl		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dibromo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidinone		I-IUPAC
in		O
a		O
reaction		O
involving		O
Favorskii		O
rearrangement		O
.		O
Antiviral		O
evaluation		O
of		O
these		O
compounds		O
revealed		O
a		O
very		O
potent		O
antiherpetic		O
activity		O
associated		O
with		O
the		O
Northern		O
thymidine		O
analogue		O
2		O
,		O
which		O
was		O
more		O
powerful		O
than		O
the		O
reference		O
standard		O
acyclovir		O
against		O
both		O
HSV		O
-		O
1		O
and		O
HSV		O
-		O
2		O
.		O
However		O
,		O
the		O
hydrogen		O
-		O
bonding		O
network		O
for		O
each		O
class		O
of		O
ligand		O
is		O
somewhat		O
different		O
and		O
the		O
number		O
of		O
hydrogen		O
bonds		O
formed		O
between		O
PKC		O
and		O
these		O
ligands		O
has		O
no		O
correlation		O
with		O
their		O
binding		O
affinities		O
.		O
Administered		O
intraperitoneally		O
for		O
5		O
consecutive		O
days		O
,		O
1c		O
was		O
as		O
effective		O
as		O
FU		O
at		O
prolonging		O
the		O
life		O
span		O
of		O
mice		O
bearing		O
P		O
-		O
388		O
leukemia		O
.		O
The		O
structure		O
-		O
activity		O
relationships		O
of		O
two		O
series		O
of		O
novel		O
retinoids		O
(		O
2		B-IUPAC
-		I-IUPAC
pyrazinylcarboxamidobenzoates		I-IUPAC
and		O
beta		B-IUPAC
-		I-IUPAC
ionylideneacetamidobenzoates		I-IUPAC
)		O
have		O
been		O
investigated		O
by		O
evaluating		O
their		O
ability		O
to		O
induce		O
differentiation		O
in		O
both		O
human		O
promyelocytic		O
leukemia		O
(		O
HL60		O
)		O
cells		O
and		O
mouse		O
embryonal		O
carcinoma		O
(		O
P19		O
)		O
cells		O
.		O
The		O
analogues		O
5-9		O
(		O
IC50		O
values		O
&		O
gt		O
;		O
100		O
microM		O
,		O
Table		O
I		O
)		O
exist		O
largely		O
in		O
the		O
3,4		O
-		O
dipseudoaxial		O
conformation		O
(		O
as		O
evidenced		O
by		O
1H		O
NMR		O
spectra		O
)		O
,		O
whereas		O
the		O
3		O
-		O
cyano		O
derivative		O
(		O
10		O
,		O
IC50		O
=		O
12.0		O
microM		O
)		O
has		O
a		O
relatively		O
high		O
population		O
of		O
the		O
3		O
-		O
pseudoequatorial		O
conformer		O
.		O
On		O
the		O
basis		O
of		O
the		O
high		O
correlation		O
between		O
adenosine		O
binding		O
affinities		O
of		O
analogously		O
substituted		O
xanthines		O
and		O
pyrazolo		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
and		O
the		O
close		O
superposition		O
of		O
the		O
heterocyclic		O
rings		O
and		O
substituents		O
that		O
is		O
apparent		O
from		O
molecular		O
models		O
of		O
these		O
two		O
series		O
,		O
it		O
is		O
hypothesized		O
they		O
fit		O
the		O
receptor		O
in		O
an		O
analogous		O
fashion		O
.		O
Moreover		O
,		O
compound		O
55		O
exhibited		O
a		O
fairly		O
high		O
ratio		O
of		O
antistereotypic		O
activity		O
to		O
cataleptogenicity		O
compared		O
with		O
haloperidol		O
and		O
metoclopramide		O
.		O
9,11		O
-		O
Secoestradiol		O
(		O
9		O
)		O
and		O
11		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
9,11		I-IUPAC
-		I-IUPAC
secoestradiol		I-IUPAC
(		O
12		O
)		O
have		O
been		O
synthesized		O
starting		O
from		O
17		B-IUPAC
-		I-IUPAC
acetoxyestradiol		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
ether		I-IUPAC
(		O
1		O
)		O
and		O
found		O
to		O
possess		O
significant		O
antifertility		O
activity		O
in		O
rats		O
.		O
The		O
permanent		O
positive		O
charge		O
on		O
the		O
distal		O
nitrogen		O
atom		O
of		O
the		O
tricyclic		O
side		O
chain		O
contribution		O
to		O
binding		O
was		O
estimated		O
as		O
&		O
gt		O
;		O
/		O
=		O
5.6		O
kcal		O
.		O
The		O
aminolysis		O
protocol		O
used		O
here		O
has		O
distinct		O
advantages		O
over		O
either		O
reductive		O
cleavage		O
or		O
preformed		O
linker		O
methods		O
described		O
previously		O
for		O
the		O
preparation		O
of		O
octreotide		O
.		O
Alkylation		O
with		O
(		B-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
chloride		I-IUPAC
yielded		O
basic		O
cyclopropanes		O
.		O
Glucuronic		O
acid		O
linked		O
prodrugs		O
of		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzylguanine		I-IUPAC
and		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyguanosine		I-IUPAC
were		O
synthesized		O
.		O
Conversion		O
of		O
this		O
oxime		O
to		O
1		B-IUPAC
-		I-IUPAC
phthalimido		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
p		I-IUPAC
-		I-IUPAC
(		I-IUPAC
carbomethoxy		I-IUPAC
)		I-IUPAC
thiophenoxy		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butanone		I-IUPAC
oxime		I-IUPAC
(		O
4		O
)		O
was		O
carried		O
out		O
by		O
its		O
reaction		O
with		O
potassium		O
phthalimide		O
using		O
crown		O
18		O
ether		O
as		O
a		O
catalyst		O
.		O
The		O
3		B-IUPAC
-		I-IUPAC
deazaguanosine		I-IUPAC
3'		I-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
cyclic		I-IUPAC
phosphate		I-IUPAC
(		O
13		O
)		O
was		O
prepared		O
from		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
cyanomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
-		I-IUPAC
imidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
phosphate		I-IUPAC
.		O
For		O
7b		O
,		O
the		O
initial		O
enzyme		O
velocity		O
is		O
not		O
a		O
saturable		O
function		O
of		O
the		O
inhibitor		O
concentration		O
and		O
the		O
initial		O
Ki		O
could		O
not		O
be		O
determined		O
(		O
Ki		O
&		O
gt		O
;		O
10		O
microM		O
)		O
.		O
Introduction		O
of		O
substituents		O
in		O
the		O
benzene		O
ring		O
of		O
the		O
spiro		B-IUPAC
[		I-IUPAC
isobenzofuran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
piperidine		I-IUPAC
]		I-IUPAC
ring		O
system		O
of		O
Lu		O
28-179		O
mainly		O
affects		O
affinity		O
for		O
sigma		O
1		O
binding		O
sites		O
.		O
Larger		O
substituents		O
were		O
well		O
-		O
tolerated		O
by		O
the		O
receptor		O
,		O
but		O
the		O
smaller		O
N		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
bound		B-MODIFIER
with		O
lower		O
affinity		O
.		O
carinii		O
and		O
the		O
T		O
.		O
Among		O
the		O
various		O
compounds		O
screened		O
,		O
methyl		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
4c		O
)		O
has		O
shown		O
the		O
highest		O
adulticidal		O
activity		O
and		O
methyl		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3		I-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
3a		O
)		O
has		O
shown		O
the		O
highest		O
microfilaricidal		O
action		O
against		O
A		O
.		O
Compounds		O
4		O
,		O
18		O
,		O
and		O
20		O
are		O
inhibitors		O
of		O
the		O
GABA		O
uptake		O
system		O
,		O
although		O
much		O
weaker		O
than		O
nipecotic		O
acid		O
and		O
(		B-IUPAC
3RS		I-IUPAC
,		I-IUPAC
4SR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxypiperidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
21		O
)		O
.		O
The		O
thiadiazolopyrimidine		O
(		O
14		O
)		O
showed		O
activity		O
at		O
three		O
dose		O
levels		O
.		O
The		O
N		O
(		O
1		O
)		O
-		O
substituents		O
evaluated		O
ranged		O
in		O
size		O
from		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
naphthalen		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
naphthalen		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
naphthalen		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
anthracen		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
anthracen		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
,		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
anthracen		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
,		O
and		O
pyren		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
.		O
These		O
target		O
compounds		O
with		O
stereochemical		O
diversity		O
were		O
synthesized		O
from		O
the		O
versatile		O
chiral		O
cyclopropane		O
units		O
(		B-PARTIUPAC
1S		I-PARTIUPAC
,		I-PARTIUPAC
2R		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyldiphenylsilyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
formylcyclopropane		I-IUPAC
(		O
6		O
and		O
7		O
,		O
respectively		O
)		O
or		O
their		O
enantiomers		O
ent		O
-		O
6		O
and		O
ent		O
-		O
7		O
.		O
For		O
the		O
latter		O
compound		O
,		O
the		O
chloroethyl		O
group		O
is		O
partially		O
(		O
at		O
pH		O
5.5		O
)		O
or		O
totally		O
(		O
at		O
pH		O
7.0		O
)		O
cyclized		O
into		O
aziridine		O
(		O
4b		O
-		O
2		O
)		O
,		O
which		O
is		O
then		O
progressively		O
hydrolyzed		O
into		O
an		O
N		B-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
group		B-MODIFIER
(		O
4b		O
-		O
3		O
)		O
.		O
Several		O
Z		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
methylenecyclopropanes		I-IUPAC
exhibited		O
in		O
vitro		O
antiviral		O
activity		O
in		O
micromolar		O
or		O
submicromolar		O
range		O
against		O
human		O
and		O
murine		O
cytomegalovirus		O
(		O
HCMV		O
and		O
MCMV		O
)		O
,		O
Epstein		O
-		O
Barr		O
virus		O
(		O
EBV		O
)		O
,		O
human		O
herpes		O
virus		O
6		O
(		O
HHV		O
-		O
6		O
)		O
,		O
varicella		O
zoster		O
virus		O
(		O
VZV		O
)		O
,		O
and		O
hepatitis		O
B		O
virus		O
(		O
HBV		O
)		O
.		O
The		O
most		O
active		O
compounds		O
strongly		O
displaced		O
[		O
(		O
3		O
)		O
H		O
]		O
colchicine		O
from		O
its		O
binding		O
site		O
in		O
the		O
tubulin		O
,		O
yielding		O
IC		O
(		O
50		O
)		O
values		O
3		O
-		O
to		O
4		O
-		O
fold		O
lower		O
than		O
that		O
of		O
colchicine		O
.		O
By		O
a		O
variety		O
of		O
synthetic		O
routes		O
,		O
we		O
have		O
synthesized		O
a		O
series		O
of		O
3,4,5		B-MODIFIER
-		I-MODIFIER
trisubstituted		I-MODIFIER
4H		B-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazoles		I-IUPAC
and		O
a		O
related		O
series		O
of		O
3H		B-IUPAC
-		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,2,4		I-IUPAC
]		I-IUPAC
triazoles		I-IUPAC
and		O
evaluated		O
them		O
in		O
vitro		O
and		O
in		O
vivo		O
as		O
angiotensin		O
II		O
(		O
AII		O
)		O
antagonists		O
.		O
Various		O
structural		O
features		O
of		O
this		O
series		O
of		O
compounds		O
that		O
may		O
have		O
an		O
affinity		O
for		O
receptor		O
binding		O
sites		O
are		O
discussed		O
.		O
The		O
coplanarity		O
of		O
trans		O
isomers		O
and		O
the		O
flexibility		O
of		O
cis		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
complexes		B-MODIFIER
allow		O
them		O
easy		O
approach		O
to		O
the		O
target		O
DNA		O
.		O
The		O
16		O
new		O
analogues		O
are		O
(		O
1		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
D		O
-		O
Tyr		O
(		O
Me		O
)		O
2		O
]		O
AVP		O
,		O
(		O
2		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
D		O
-		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Val4		O
,		O
delta		O
3		O
-		O
Pro7		O
]		O
AVP		O
,		O
(		O
3		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
D		O
-		O
Tyr		O
-		O
(		O
Et		O
)		O
2		O
,		O
Val4		O
,		O
Lys8		O
]		O
VP		O
,		O
(		O
4		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
D		O
-		O
Tyr		O
(		O
Et		O
)		O
2		O
,		O
Val4		O
,		O
Cit8		O
]		O
VP		O
,		O
(		O
5		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
]		O
AVT		O
,		O
(		O
6		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Lys8		O
]		O
VT		O
,		O
(		O
7		O
)		O
dP		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
]		O
AVT		O
,		O
(		O
8		O
)		O
dP		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Val4		O
]		O
AVT		O
,		O
(		O
9		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
D		O
-		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Val4		O
]		O
AVT		O
,		O
(		O
10		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
D		O
-		O
Phe2		O
,		O
Val4		O
]		O
AVT		O
,		O
(		O
11		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Thr4		O
]		O
OVT		O
,		O
(		O
12		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Thr4		O
,		O
Ala		O
-		O
NH2		O
(		O
9		O
)		O
]		O
OVT		O
,		O
(		O
13		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Thr4		O
,		O
Leu		O
-		O
NH2		O
(		O
9		O
)		O
]		O
OVT		O
,		O
(		O
14		O
)		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Thr4		O
,		O
Arg		O
-		O
NH2		O
(		O
9		O
)		O
]		O
OVT		O
,		O
(		O
15		O
)		O
desGly		O
-		O
NH2		O
(		O
9		O
)		O
,		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Thr4		O
]		O
OVT		O
,		O
(		O
16		O
)		O
desGly9		O
,		O
d		O
(		O
CH2		O
)		O
5		O
[		O
Tyr		O
(		O
Me		O
)		O
2		O
,		O
Thr4		O
]		O
OVT		O
.		O
A		O
series		O
of		O
2		B-MODIFIER
-		I-MODIFIER
(		I-MODIFIER
4		I-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
homo		I-IUPAC
)		I-IUPAC
piperazinyl		I-IUPAC
)		I-IUPAC
benzimidazoles		I-IUPAC
was		O
prepared		O
and		O
tested		O
for		O
H1		O
-		O
antihistaminic		O
activity		O
in		O
vitro		O
and		O
in		O
vivo		O
.		O
All		O
analogues		O
were		O
tested		O
in		O
rats		O
for		O
agonistic		O
and		O
antagonistic		O
activities		O
in		O
oxytocic		O
(		O
in		O
vitro		O
,		O
without		O
and		O
with		O
Mg2+		O
,		O
and		O
in		O
vivo		O
)		O
assays		O
as		O
well		O
as		O
by		O
antidiuretic		O
and		O
vasopressor		O
assays		O
.		O
A		O
series		O
of		O
cyclic		O
analogues		O
was		O
synthesized		O
having		O
the		O
general		O
formula		O
cyclo		O
(		O
25-29		O
)		O
[		O
MeTyr1		O
,		O
-		O
Ala15		O
,		O
Xaa25		O
,		O
Nle27		O
,		O
Yaa29+		O
+		O
+		O
]		O
-		O
GHRH		O
(		O
1-29		O
)		O
-		O
NH2		O
,		O
where		O
Xaa		O
and		O
Yaa		O
represent		O
the		O
bridgehead		O
residues		O
of		O
a		O
side		O
-		O
chain		O
cystine		O
or		O
[		O
i		O
-		O
(		O
i		O
+		O
4		O
)		O
]		O
lactam		O
ring		O
.		O
DNA		O
fragmentation		O
and		O
annexin		O
V		O
-		O
FITC		O
positive		O
cells		O
were		O
taken		O
as		O
parameters		O
of		O
apoptosis		O
whereas		O
NFkappa		O
-		O
B		O
activity		O
was		O
tested		O
by		O
the		O
expression		O
of		O
the		O
reporter		O
vector		O
kappaB		O
-		O
luciferase		O
by		O
TNF		O
-		O
alpha		O
in		O
Hela		O
cells		O
.		O
According		O
to		O
the		O
data		O
presented		O
here		O
,		O
(		O
FMS		O
)		O
(		O
3		O
)		O
-		O
insulin		O
represents		O
a		O
typical		O
prodrug		O
:		O
a		O
compound		O
which		O
by		O
itself		O
shows		O
only		O
marginal		O
activity		O
but		O
over		O
time		O
it		O
is		O
chemically		O
hydrolyzed		O
to		O
the		O
fully		O
active		O
hormone		O
.		O
Substitution		O
of		O
halogens		O
in		O
the		O
phenyl		B-IUPAC
ring		B-MODIFIER
increased		O
potency		O
and		O
selectivity		O
for		O
the		O
beta		O
(		O
3		O
)		O
-		O
adrenoceptor		O
,		O
and		O
this		O
was		O
dependent		O
upon		O
the		O
position		O
of		O
the		O
halogens		O
.		O
Substrate		O
and		O
inhibitor		O
properties		O
indicated		O
that		O
the		O
ATP		O
derivatives		O
are		O
potential		O
exco		O
-		O
ATP		O
-		O
site		O
-		O
directed		O
inactivators		O
of		O
hexokinases		O
,		O
adenylate		O
kinases		O
,		O
and		O
pyruvate		O
kinases		O
.		O
Glycosylated		O
antitumor		O
ether		O
lipids		O
(		O
GAELs		O
)		O
,		O
analogs		O
of		O
1		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
octadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycero		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phosphocholine		I-IUPAC
(		O
1		O
,		O
ET		O
-		O
18		O
-		O
OCH3		O
,		O
edelfosine		O
)		O
,		O
were		O
synthesized		O
in		O
good		O
overall		O
yields		O
by		O
glycosylation		O
of		O
1		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycerol		I-IUPAC
and		O
tested		O
for		O
in		O
vitro		O
antineoplastic		O
activity		O
against		O
a		O
variety		O
of		O
murine		O
and		O
human		O
tumor		O
cell		O
lines		O
.		O
However		O
,		O
several		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboalkoxy		I-IUPAC
-		I-IUPAC
substituted		I-IUPAC
-		I-IUPAC
3alpha		I-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
methoxy		I-IUPAC
]		I-IUPAC
tropane		I-IUPAC
analogues		B-MODIFIER
were		O
discovered		O
to		O
stimulate		O
locomotor		O
activity		O
and		O
substitute		O
in		O
subjects		O
trained		O
to		O
discriminate		O
cocaine		O
,		O
suggesting		O
a		O
role		O
of		O
the		O
2		O
-		O
position		O
substituent		O
in		O
mediating		O
these		O
cocaine		O
-		O
like		O
actions		O
.		O
Synthetic		O
routes		O
to		O
a		O
series		O
of		O
mono		B-PARTIUPAC
-		I-PARTIUPAC
and		O
difluorinated		B-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		O
substituted		B-MODIFIER
-		O
phenyl		B-IUPAC
)		I-IUPAC
benzothiazoles		I-IUPAC
have		O
been		O
devised		O
.		O
In		O
the		O
assay		O
for		O
D		O
-		O
2		O
receptor		O
mediated		O
inhibition		O
of		O
adenylate		O
cyclase		O
activity		O
,		O
all		O
the		O
tested		O
compounds		O
behaved		O
as		O
D		O
-		O
2		O
agonists		O
;		O
N		B-PARTIUPAC
-		I-PARTIUPAC
n		I-PARTIUPAC
-		I-PARTIUPAC
propyl		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
2		I-PARTIUPAC
(		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
hydroxyphenyl		I-PARTIUPAC
)		I-PARTIUPAC
ethyl		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
(		O
18d		O
)		O
and		O
N		B-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
ethylamine		I-IUPAC
(		O
18b		O
)		O
were		O
more		O
effective		O
than		O
DA		O
or		O
2a		O
.		O
With		O
the		O
goal		O
of		O
developing		O
high		O
affinity		O
P2		O
-		O
purinoceptor		O
-		O
selective		O
agonist		O
,		O
we		O
have		O
synthesized		O
a		O
series		O
of		O
analogues		O
of		O
adenine		O
nucleotides		O
modified		O
on		O
the		O
purine		O
ring		O
as		O
chain		O
-		O
extended		O
2		O
-		O
thioethers		O
or		O
as		O
N6		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		O
substituted		B-MODIFIER
compounds		O
.		O
They		O
were		O
also		O
examined		O
for		O
their		O
inhibition		O
of		O
the		O
growth		O
of		O
the		O
L1210		O
cell		O
line		O
and		O
of		O
two		O
mutant		O
L1210		O
cell		O
lines		O
,		O
the		O
L1210		O
:		O
R7A		O
that		O
overproduces		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
and		O
the		O
L1210		O
:		O
1565		O
that		O
has		O
impaired		O
uptake		O
of		O
reduced		O
folates		O
.		O
Regression		O
analysis		O
suggested		O
a		O
requirement		O
for		O
optimally		O
sized		O
,		O
hydrophobic		O
5		O
-		O
and		O
7		O
-		O
substituents		O
,		O
with		O
bulk		O
tolerance		O
being		O
greater		O
at		O
the		O
5		O
-		O
position		O
.		O
Novel		O
3		O
-		O
substituted		O
analogues		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
3		B-IUPAC
-		I-IUPAC
deazacytidine		I-IUPAC
,		O
3		O
)		O
and		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
3		B-IUPAC
-		I-IUPAC
deazauridine		I-IUPAC
,		O
4		O
)		O
have		O
been		O
synthesized		O
and		O
tested		O
for		O
antitumor		O
and		O
antiviral		O
activity		O
.		O
The		O
conversion		O
of		O
the		O
monophenols		O
into		O
catecholic		O
metabolites		O
is		O
only		O
1-5%		O
,		O
and		O
the		O
further		O
conversion		O
of		O
these		O
catecholic		O
metabolites		O
into		O
methoxylated		O
analogues		O
is		O
very		O
rapid		O
.		O
The		O
major		O
factor		O
influencing		O
the		O
opioid		O
binding		O
of		O
the		O
similar		O
-		O
sized		O
heterocyclic		O
compounds		O
was		O
relative		O
lipophilicity		O
,		O
which		O
outweighed		O
electronic		O
character		O
.		O
For		O
the		O
preparation		O
of		O
the		O
iodine		O
-		O
125		O
-		O
labeled		O
benzamide		O
with		O
higher		O
specific		O
activity		O
,		O
this		O
method		O
was		O
unsuccessful		O
and		O
utilization		O
of		O
the		O
corresponding		O
tri		B-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butyltin		I-IUPAC
derivative		B-MODIFIER
was		O
required		O
.		O
Biological		O
activities		O
in		O
L1210		O
(		O
murine		O
leukemia		O
)		O
,		O
alpha		B-IUPAC
-		I-IUPAC
difluoromethylornithine		I-IUPAC
(		O
DFMO		O
)		O
-		O
treated		O
L1210		O
,		O
and		O
Chinese		O
hamster		O
ovary		O
(		O
CHO		O
)		O
and		O
its		O
polyamine		O
transport		O
-		O
deficient		O
mutant		O
(		O
CHO		O
-		O
MG		O
)		O
cell		O
lines		O
were		O
investigated		O
via		O
IC		O
(		O
50		O
)		O
cytotoxicity		O
determinations		O
.		O
A		O
series		O
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
arylalkyl		I-IUPAC
)		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylglyoxylylamides		I-IUPAC
(		O
4-8		O
)		O
was		O
synthesized		O
as		O
ligands		O
of		O
the		O
benzodiazepine		O
receptor		O
(		O
BzR		O
)		O
and		O
tested		O
for		O
their		O
ability		O
to		O
displace		O
[		O
(		O
3		O
)		O
H		O
]		O
flumazenil		O
from		O
bovine		O
brain		O
membranes		O
.		O
DCC		O
-		O
mediated		O
cyclization		O
of		O
17		O
,		O
followed		O
by		O
debenzylation		O
,		O
gave		O
pyrazofurin		O
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
cyclic		I-IUPAC
)		I-IUPAC
phosphate		I-IUPAC
(		O
21b		O
)		O
.		O
All		O
analogs		O
were		O
evaluated		O
in		O
the		O
in		O
vitro		O
5		O
-		O
HT1A		O
and		O
D2		O
binding		O
assays		O
and		O
selected		O
analogs		O
were		O
investigated		O
further		O
in		O
biochemical		O
and		O
behavioral		O
tests		O
.		O
The		O
strongly		O
increased		O
stereoselectivity		O
of		O
2		O
,		O
4		O
,		O
and		O
5		O
as		O
compared		O
to		O
that		O
of		O
8		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
di		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylamino		I-IUPAC
)		I-IUPAC
tetralin		I-IUPAC
(		O
8		O
-		O
OH		O
-		O
DPAT		O
;		O
1		O
)		O
is		O
rationalized		O
on		O
the		O
basis		O
of		O
steric		O
factors		O
.		O
Reaction		O
of		O
bromide		O
1		O
with		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
benzamido		I-IUPAC
)		I-IUPAC
chloromercuriopurine		I-IUPAC
followed		O
by		O
saponification		O
yielded		O
9		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
threo		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
adenine		I-IUPAC
(		O
8		O
)		O
.		O
The		O
most		O
potent		O
compound		O
,		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dimethyldodecanamide		I-IUPAC
(		O
35		O
,		O
TEI		O
-		O
6522		O
)		O
,		O
showed		O
significant		O
ACAT		O
inhibitory		O
activity		O
(		O
rabbit		O
small		O
intestine		O
IC50		O
=		O
13		O
nM		O
,		O
rabbit		O
liver		O
IC50		O
=		O
16		O
nM		O
)		O
,		O
foam		O
cell		O
formation		O
inhibitory		O
activity		O
(		O
rat		O
peritoneal		O
macrophage		O
IC50		O
=		O
160		O
nM		O
)		O
,		O
and		O
extremely		O
potent		O
serum		O
cholesterol		O
-		O
lowering		O
activity		O
in		O
cholesterol		O
-		O
fed		O
rats		O
(		O
61%		O
at		O
a		O
dose		O
of		O
0.1		O
mg		O
/		O
kg		O
/		O
day		O
po		O
)		O
.		O
[		O
125I		O
]		O
2a		O
is		O
now		O
being		O
used		O
clinically		O
in		O
imaging		O
and		O
radiotherapy		O
of		O
catecholamine		O
tumors		O
,		O
such		O
as		O
pheochromocytoma		O
.		O
All		O
alpha		O
,		O
beta		O
-		O
unsaturated		O
carbonyl		O
compounds		O
obtained		O
exhibited		O
antiviral		O
activity		O
and		O
cytotoxicity		O
.		O
A		O
detailed		O
structure		O
-		O
activity		O
analysis		O
was		O
carried		O
out		O
using		O
eight		O
1		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
(		I-IUPAC
aralkyl		I-IUPAC
)		I-IUPAC
nipecotamides		I-IUPAC
(		O
type		O
5		O
)		O
,		O
33		O
bis		B-IUPAC
-		I-IUPAC
nipecotamidoalkanes		I-IUPAC
and		O
aralkanes		B-IUPAC
(		O
type		O
6		O
)		O
,		O
and		O
7		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
nipecotoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
piperazines		I-IUPAC
(		O
type		O
7		O
)		O
as		O
inhibitors		O
of		O
human		O
platelet		O
aggregation		O
.		O
Several		O
compounds		O
display		O
high		O
affinity		O
to		O
serotonin		O
5		O
-		O
HT1A		O
receptors		O
in		O
spite		O
of		O
major		O
differences		O
in		O
steric		O
bulk		O
and		O
electronic		O
properties		O
of		O
the		O
various		O
C11		O
-		O
substituents		O
.		O
Convenient		O
and		O
efficient		O
methods		O
were		O
developed		O
for		O
preparing		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluorouracil		I-IUPAC
(		O
Thf		O
-		O
FU		O
,		O
3		O
)		O
[		O
trade		O
name		O
,		O
Futraful		O
(		O
Ftorafur		O
)		O
or		O
FT		O
-		O
207		O
]		O
,		O
which		O
is		O
used		O
clinically		O
as		O
an		O
antitumor		O
agent		O
,		O
and		O
1,3		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluorouracil		I-IUPAC
(		O
Thf2		O
-		O
FU		O
,		O
4		O
)		O
.		O
The		O
cis		B-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethylindolin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
imidazoline		I-IUPAC
6a		O
is		O
an		O
alpha		O
2		O
-		O
adrenergic		O
agonist		O
equal		O
in		O
potency		O
to		O
clonidine		O
in		O
vitro		O
,		O
while		O
the		O
trans		B-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethylindolin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
imidazoline		I-IUPAC
6b		O
is		O
a		O
moderately		O
potent		O
alpha		O
2		O
-		O
adrenergic		O
antagonist		O
.		O
Thiazolo		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
35		O
were		O
prepared		O
from		O
6		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
'		I-IUPAC
-		I-IUPAC
bipyridin		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
amines		I-IUPAC
30		O
and		O
32		O
via		O
a		O
four		O
-		O
step		O
sequence		O
.		O
Two		O
-		O
dimensional		O
nuclear		O
Overhauser		O
effect		O
(		O
NOESY		O
)		O
spectra		O
of		O
the		O
tomaymycin		O
-		O
d		O
(		O
ATGCAT		O
)		O
2		O
duplex		O
adduct		O
show		O
that		O
the		O
adducts		O
are		O
relatively		O
nondistortive		O
.		O
By		O
this		O
approach		O
compounds		O
such		O
as		O
(		B-IUPAC
3R		I-IUPAC
,		I-IUPAC
5S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
adamantyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chlorobenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxymet		I-IUPAC
hyl		I-IUPAC
aminocarbonyl		I-IUPAC
-		I-IUPAC
2,7		I-IUPAC
-		I-IUPAC
dioxo		I-IUPAC
-		I-IUPAC
2,3,4,5,6,7		I-IUPAC
-		I-IUPAC
hexahydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
h		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1		I-IUPAC
,		I-IUPAC
4		I-IUPAC
]		I-IUPAC
diazonine		I-IUPAC
(		O
32		O
)		O
were		O
prepared		O
.		O
carinii		O
or		O
T		O
.		O
The		O
oral		O
activity		O
of		O
the		O
prodrugs		O
was		O
modest		O
with		O
only		O
one		O
showing		O
2/4		O
cures		O
in		O
the		O
same		O
mouse		O
model		O
.		O
Another		O
derivative		O
of		O
this		O
compound		O
,		O
namely		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
(		O
5a		O
)		O
,		O
exhibited		O
the		O
highest		O
activity		O
against		O
L		O
.		O
Six		O
new		O
B		O
-		O
ring		O
analogues		O
of		O
the		O
nonpolyglutamatable		O
antifolate		O
Nalpha		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxypteroyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
Ndelta		I-IUPAC
-		I-IUPAC
hemiphthaloy		I-IUPAC
l		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
ornithine		I-IUPAC
(		O
PT523		O
,		O
3		O
)		O
were		O
synthesized		O
with		O
a		O
view		O
to		O
determining		O
the		O
effect		O
of		O
modifications		O
at		O
the		O
5		O
-		O
and		O
/		O
or		O
8		O
-		O
position		O
on		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
binding		O
and		O
tumor		O
cell		O
growth		O
inhibition		O
.		O
Methods		O
employed		O
for		O
the		O
preparation		O
of		O
tetramethoxydiphenylethane		B-IUPAC
intermediates		O
involved		O
(		O
1		O
)		O
arylmethyl		O
bromide		O
coupling		O
and		O
(		O
2		O
)		O
catalytic		O
hydrogenation		O
of		O
stilbene		O
intermediates		O
derived		O
via		O
Wittig		O
reaction		O
of		O
(		O
arylmethyl		O
)		O
phosphonium		O
salts		O
with		O
aryl		O
aldehydes		O
.		O
This		O
effect		O
on		O
TH		O
was		O
blocked		O
by		O
the		O
putative		O
sigma		O
-		O
receptor		O
antagonist		O
BMY		O
-		O
14802		O
,		O
suggesting		O
involvement		O
of		O
a		O
novel		O
neuromodulatory		O
sigma		O
-		O
like		O
receptor		O
.		O
High		O
specific		O
activity		O
[		O
(		O
123		O
)		O
I		O
]		O
ZIENT		O
and		O
[		O
(		O
123		O
)		O
I		O
]		O
EIENT		O
were		O
synthesized		O
in		O
45%		O
(		O
n		O
=		O
5		O
)		O
and		O
42%		O
(		O
n		O
=		O
4		O
)		O
radiochemical		O
yield		O
(		O
decay		O
-		O
corrected		O
to		O
end		O
of		O
bombardment		O
(		O
EOB		O
)		O
)		O
,		O
respectively		O
,		O
by		O
preparation		O
of		O
the		O
precursor		O
carbomethoxy		B-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
trimethylstannylethenyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
nortropane		I-IUPAC
(		O
7		O
)		O
and		O
2beta		B-IUPAC
-		I-IUPAC
carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
tributylstannylethenyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
nortropane		I-IUPAC
(		O
9		O
)		O
,		O
respectively		O
,		O
followed		O
by		O
treatment		O
with		O
no		O
carrier		O
-		O
added		O
sodium		O
[		O
(		O
123		O
)		O
I		O
]		O
iodide		O
and		O
hydrogen		O
peroxide		O
in		O
ethanolic		O
HCl		O
.		O
The		O
characteristics		O
of		O
these		O
reactions		O
were		O
very		O
similar		O
to		O
those		O
previously		O
reported		O
for		O
the		O
oxidation		O
of		O
NOHA		O
by		O
NOS		O
:		O
(		O
i		O
)		O
the		O
strict		O
requirement		O
of		O
NOS		O
containing		O
(		B-IUPAC
6R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5,6,7,8		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
biopterin		I-IUPAC
,		O
reduced		O
nicotinamide		O
adenine		O
dinucleotide		O
phosphate		O
,		O
and		O
O		O
(		O
2		O
)		O
for		O
the		O
oxidation		O
to		O
occur		O
,		O
(		O
ii		O
)		O
the		O
formation		O
of		O
NO		O
and		O
the		O
corresponding		O
urea		O
in		O
a		O
1		O
:		O
1		O
molar		O
ratio		O
,		O
and		O
(		O
iii		O
)		O
a		O
strong		O
inhibitory		O
effect		O
of		O
the		O
classical		O
NOS		O
inhibitors		O
such		O
as		O
N		B-IUPAC
(		I-IUPAC
omega		I-IUPAC
)		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
and		O
S		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
iso		I-IUPAC
-		I-IUPAC
thiourea		I-IUPAC
.		O
5		O
-		O
Chloro		O
-		O
dUMP		O
,		O
5		O
-		O
bromo		O
-		O
dUMP		O
,		O
and		O
5		O
-		O
iodo		O
-		O
dUMP		O
,		O
similar		O
to		O
dTMP		O
,		O
did		O
not		O
cause		O
a		O
time		O
-		O
dependent		O
inactivation		O
of		O
the		O
enzyme		O
.		O
The		O
structure		O
-		O
affinity		O
relationships		O
of		O
these		O
2		O
-		O
substituted		O
aporphines		O
suggest		O
that		O
secondary		O
binding		O
sites		O
of		O
D2		O
receptors		O
interact		O
with		O
2		O
-		O
substituents		O
on		O
the		O
A		O
ring		O
of		O
aporphines		O
through		O
H		O
-		O
bonding		O
.		O
Several		O
of		O
the		O
novel		O
compounds		O
were		O
also		O
evaluated		O
for		O
their		O
ability		O
in		O
vivo		O
to		O
inhibit		O
clonic		O
seizures		O
induced		O
by		O
a		O
15		O
mg		O
/		O
kg		O
(		O
ip		O
)		O
dose		O
of		O
methyl		B-IUPAC
6,7		I-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
carboline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
DMCM		O
)		O
.		O
The		O
epimers		O
(		O
-		O
)		O
-		O
3		O
and		O
(		O
+		O
)		O
-		O
4		O
proved		O
to		O
be		O
agonists		O
at		O
the		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptors		O
,		O
with		O
a		O
potency		O
comparable		O
to		O
that		O
of		O
5		B-IUPAC
-		I-IUPAC
hydroxytryptamine		I-IUPAC
.		O
The		O
"		O
predicted		O
"		O
binding		O
model		O
for		O
phorbol		B-IUPAC
-		I-IUPAC
13		I-IUPAC
-		I-IUPAC
acetate		I-IUPAC
is		O
virtually		O
identical		O
to		O
the		O
experimentally		O
determined		O
binding		O
model		O
for		O
this		O
ligand		O
.		O
Orotyl		B-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucine		I-IUPAC
,		O
5		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
succinamoyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
alanyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucine		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyrimidinone		I-IUPAC
[		O
a		O
5		B-IUPAC
-		I-IUPAC
fluorocytosine		I-IUPAC
derivative		B-MODIFIER
]		O
,		O
and		O
5		B-IUPAC
-		I-IUPAC
fluoroorotyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
leucine		I-IUPAC
all		O
inhibited		O
the		O
uptake		O
of		O
trimethionine		O
into		O
C		O
.		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Benzyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenylpiperidines		I-IUPAC
and		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylmethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidinols		I-IUPAC
and		O
the		O
corresponding		O
methyl		O
ethers		O
and		O
esters		O
display		O
weak		O
to		O
modest		O
antitetrabenazine		O
activity		O
.		O
Compounds		O
18		O
,		O
19b		O
,		O
20b		O
,		O
and		O
23b		O
also		O
exhibited		O
significant		O
inhibitory		O
effects		O
on		O
the		O
growth		O
of		O
L1210		O
and		O
P388		O
leukemias		O
and		O
Lewis		O
lung		O
carcinoma		O
cells		O
in		O
vitro		O
,		O
whereas		O
B16		O
melanoma		O
cells		O
were		O
less		O
sensitive		O
to		O
growth		O
inhibition		O
by		O
these		O
compounds		O
.		O
The		O
novel		O
agonists		O
described		O
inhibit		O
6		B-IUPAC
,		I-IUPAC
7		I-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
carboline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
-		O
induced		B-MODIFIER
seizures		I-MODIFIER
,		O
and		O
in		O
mouse		O
locomotor		O
activity		O
higher		O
doses		O
are		O
required		O
to		O
reach		O
ED		O
(		O
50		O
)		O
values		O
than		O
for		O
reference		O
A		O
(		O
1		O
)		O
agonists		O
.		O
This		O
compound		O
shows		O
low		O
cytotoxicity		O
in		O
human		O
peripheral		O
blood		O
mononuclear		O
cells		O
and		O
also		O
has		O
favorable		O
properties		O
in		O
vivo		O
.		O
Several		O
diarylguanidines		O
structurally		O
related		O
to		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
o		I-IUPAC
-		I-IUPAC
tolylguanidine		I-IUPAC
(		O
DTG		O
)		O
,		O
a		O
known		O
selective		O
sigma		O
receptor		O
ligand		O
,		O
were		O
synthesized		O
and		O
evaluated		O
in		O
in		O
vitro		O
radioligand		O
displacement		O
assays		O
,		O
with		O
rat		O
or		O
guinea		O
pig		O
brain		O
membrane		O
homogenates		O
,		O
using		O
the		O
NMDA		O
receptor		O
ion		O
channel		O
site		O
specific		O
radioligand		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
10		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
,		I-IUPAC
11		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
a		I-IUPAC
,		I-IUPAC
d		I-IUPAC
]		I-IUPAC
cyclohepten		I-IUPAC
-		I-IUPAC
5		I-IUPAC
,		I-IUPAC
10		I-IUPAC
-		I-IUPAC
imine		I-IUPAC
(		O
MK		O
-		O
801		O
,		O
3		O
)		O
,		O
and		O
the		O
sigma		O
receptor		O
-		O
specific		O
radioligand		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
o		I-IUPAC
-		I-IUPAC
tolylguanidine		I-IUPAC
(		O
DTG		O
,		O
5		O
)		O
.		O
Reaction		O
conditions		O
for		O
the		O
Wittig		O
condensation		O
were		O
developed		O
using		O
the		O
tributylphosphorane		O
prepared		O
from		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
pteridinediamine		I-IUPAC
(		O
7b		O
)		O
as		O
a		O
model		O
.		O
[		O
1		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylisoleucine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
]		O
-		O
(		O
I		O
)		O
,		O
[		O
1		B-IUPAC
-		I-IUPAC
dimethylglycine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
]		O
-		O
(		O
II		O
)		O
,		O
[		O
1		B-IUPAC
-		I-IUPAC
guanidineacetic		I-IUPAC
acid		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
]		O
-		O
(		O
III		O
)		O
,		O
des		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
aspartic		I-IUPAC
acid		I-IUPAC
-		I-IUPAC
[		I-IUPAC
8		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
]		I-IUPAC
-		O
(		O
IV		O
)		O
,		O
and		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methylserine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
(		O
V		O
)		O
were		O
synthesized		O
by		O
Merrifield		O
's		O
solid		O
-		O
phase		O
procedure		O
to		O
study		O
the		O
effect		O
of		O
(		O
a		O
)		O
substituents		O
in		O
position		O
1		O
on		O
the		O
antagonistic		O
activity		O
of		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
,		O
and		O
(		O
b		O
)		O
a		O
change		O
in		O
size		O
and		O
branching		O
in		O
position		O
8		O
of		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methylthreonine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
.		O
The		O
sulfoxide		O
was		O
the		O
least		O
active		O
of		O
the		O
heteroretinoids		O
.		O
This		O
suggested		O
the		O
possibility		O
of		O
constraining		O
the		O
N		O
-		O
terminus		O
by		O
the		O
introduction		O
of		O
a		O
cyclo		O
(		O
1-3		O
)		O
scaffold		O
.		O
The		O
rest		O
of		O
the		O
ligands		O
had		O
poorer		O
affinities		O
with		O
Ki		O
values		O
between		O
10		O
and		O
28		O
microM		O
.		O
However		O
,		O
the		O
very		O
interesting		O
observation		O
was		O
made		O
that		O
,		O
when		O
inhibiting		O
COMT		O
by		O
means		O
of		O
tropolone		O
and		O
subsequently		O
treating		O
the		O
rats		O
with		O
high		O
doses		O
of		O
(		O
S		O
)		O
-		O
(		O
-		O
)		O
-		O
3		O
-		O
PPP		O
(		O
ip		O
)		O
,		O
postsynaptic		O
dopaminergic		O
activity		O
was		O
elicited		O
.		O
The		O
2		B-IUPAC
-		I-IUPAC
styryl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
propoxy		I-IUPAC
derivative		B-MODIFIER
,		O
20		O
,		O
of		O
the		O
furanochromone		O
visnagin		O
was		O
30		O
-		O
fold		O
selective		O
for		O
human		O
A3		O
receptors		O
vs		O
either		O
rat		O
A1		O
or		O
A2A		O
receptors		O
.		O
Several		O
of		O
the		O
new		O
compounds		O
(		O
4-6		O
a		O
-		O
ej		O
-		O
l		O
)		O
were		O
evaluated		O
for		O
their		O
ability		O
to		O
inhibit		O
the		O
growth		O
of		O
L1210		O
murine		O
leukemic		O
cells		O
.		O
Also		O
,		O
activity		O
was		O
diminished		O
or		O
destroyed		O
when		O
1		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
dihydropteridines		I-IUPAC
were		O
oxidized		O
to		O
1		B-IUPAC
-		I-IUPAC
deazapteridines		I-IUPAC
or		O
reduced		O
to		O
1		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
-		I-IUPAC
5,6,7,8		I-IUPAC
-		I-IUPAC
tetrahydropteridines		I-IUPAC
.		O
These		O
four		O
molecules		O
were		O
evaluated		O
in		O
murine		O
leukemia		O
L1210		O
cells		O
for		O
their		O
impact		O
on		O
cell		O
proliferation		O
(		O
48		O
-		O
and		O
96		O
-		O
h		O
IC		O
(		O
50		O
)		O
values		O
)		O
,		O
their		O
ability		O
to		O
compete		O
with		O
spermidine		O
for		O
the		O
polyamine		O
transport		O
apparatus		O
(		O
K		O
(		O
i		O
)		O
)		O
,		O
and		O
their		O
intracellular		O
accumulation		O
.		O
N6		O
-		O
Methyl		O
-		O
ATP		O
was		O
inactive		O
at		O
P2X		O
-		O
receptors		O
,		O
and		O
approximately		O
equipotent		O
to		O
ATP		O
at		O
taenia		O
coil		O
P2Y		O
-		O
receptors		O
.		O
Compound		O
13		O
(		O
methylhistaprodifen		O
;		O
N		B-IUPAC
(		I-IUPAC
alpha		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
diphenylpropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
ethanamine		I-IUPAC
)		O
is		O
the		O
most		O
potent		O
histamine		O
H		O
(		O
1		O
)		O
-		O
receptor		O
agonist		O
reported		O
so		O
far		O
in		O
the		O
literature		O
and		O
may		O
become		O
a		O
valuable		O
tool		O
for		O
the		O
study		O
of		O
physiological		O
and		O
pathophysiological		O
H		O
(		O
1		O
)		O
-		O
receptor		O
-		O
mediated		O
effects		O
.		O
b		O
.		O
These		O
include		O
2'		B-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
difluoro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
(		O
13		O
)		O
,		O
its		O
arabino		O
analogue		O
19		O
,		O
arabino		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylcytosine		I-IUPAC
analogue		O
21		O
,		O
3'		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
didehydro		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
fluorothymidine		I-IUPAC
(		O
25		O
)		O
,		O
3'		B-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
(		O
29		O
)		O
,		O
2'		B-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
(		O
31		O
)		O
,		O
and		O
2'		B-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
(		O
37		O
)		O
.		O
In		O
this		O
study		O
,		O
the		O
position		O
of		O
this		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
substituent		B-MODIFIER
was		O
transferred		O
from		O
the		O
omega		O
-		O
phenyl		O
group		O
to		O
the		O
benzyl		O
or		O
phenyl		O
group		O
located		O
on		O
the		O
4		O
-		O
position		O
of		O
the		O
piperidine		O
ring		O
.		O
However		O
,		O
possible		O
conformations		O
of		O
the		O
first		O
residue		O
differ		O
and		O
depend		O
on		O
the		O
covalent		O
constraints		O
incorporated		O
into		O
the		O
side		O
chain		O
.		O
Competition		O
binding		O
experiments		O
with		O
[		O
(		O
3		O
)		O
H		O
]		O
NKA		O
were		O
performed		O
using		O
cloned		O
human		O
NK		O
-		O
2		O
receptors		O
expressed		O
in		O
CHO		O
cells		O
.		O
Racemic		O
6		O
and		O
11		O
did		O
not		O
substitute		O
in		O
(		O
S		O
)		O
-		O
amphetamine		O
-		O
trained		O
rats		O
.		O
The		O
high		O
specific		O
activity		O
one		O
-		O
step		O
radiolabeling		O
preparation		O
and		O
high		O
specificity		O
and		O
selectivity		O
of		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
R		O
)		O
-		O
FIPCT		O
and		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
S		O
)		O
-		O
FIPCT		O
for		O
DAT		O
indicate		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
R		O
)		O
-		O
FIPCT		O
and		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
S		O
)		O
-		O
FIPCT		O
are		O
potential		O
radioligands		O
for		O
mapping		O
brain		O
DAT		O
in		O
humans		O
using		O
PET		O
.		O
Their		O
structures		O
of		O
platinum		O
complexes		O
were		O
elucidated		O
from		O
circular		O
dichroism		O
and		O
13C		O
NMR		O
spectral		O
analyses		O
,		O
and		O
it		O
has		O
been		O
concluded		O
that		O
the		O
cyclohexane		O
ring		O
of		O
cis		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
cyclohexanediamine		I-IUPAC
is		O
nearly		O
perpendicular		O
to		O
the		O
chelate		O
ring		O
,		O
while		O
both		O
rings		O
of		O
trans		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
cyclohexanediamine		I-IUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
complexes		B-MODIFIER
lie		O
in		O
a		O
common		O
plane		O
.		O
Additional		O
small		O
substituents		O
on		O
the		O
guanidine		O
nitrogen		O
atoms		O
bearing		O
the		O
aryl		O
rings		O
resulted		O
in		O
tri		O
-		O
and		O
tetrasubstituted		O
guanidine		O
derivatives		O
which		O
retained		O
affinity		O
for		O
NMDA		O
receptor		O
ion		O
channel		O
sites		O
but		O
exhibited		O
a		O
significant		O
reduction		O
in		O
their		O
affinities		O
for		O
sigma		O
receptors		O
.		O
mu		O
binding		O
was		O
variable		O
,		O
with		O
KiS		O
in		O
excess		O
of		O
10,000		O
nM		O
for		O
most		O
analogs		O
,		O
and		O
all		O
of		O
the		O
analogs		O
bound		O
poorly		O
to		O
k		O
receptors		O
.		O
However		O
,		O
glycosylation		O
of		O
the		O
sodium		O
salt		O
of		O
4		O
with		O
1		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluoyl		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
erythro		I-IUPAC
-		I-IUPAC
pentofurano		I-IUPAC
se		I-IUPAC
(		O
17		O
)		O
gave		O
exclusively		O
the		O
beta		O
-		O
anomers		O
(		O
19		O
and		O
21		O
)		O
in		O
good		O
yield		O
.		O
Crucially		O
,		O
these		O
studies		O
revealed		O
a		O
very		O
constrained		O
structure		O
-		O
activity		O
relationship		O
at		O
the		O
2		O
-		O
position		O
of		O
the		O
benzopyranone		O
and		O
pyrimido		B-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
isoquinolin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
pharmacophore		B-MODIFIER
,		O
with		O
only		O
a		O
2		B-IUPAC
-		I-IUPAC
morpholino		I-IUPAC
or		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
methylmorpholino		I-IUPAC
)		I-IUPAC
group		B-MODIFIER
being		O
tolerated		O
at		O
this		O
position		O
.		O
This		O
derivative		O
inhibited		O
FT		O
with		O
an		O
IC50		O
of		O
0.6		O
nM		O
and		O
inhibited		O
anchorage		O
-		O
independent		O
growth		O
of		O
stably		O
transformed		O
NIH		O
-		O
3T3		O
fibroblast		O
cells		O
by		O
50%		O
at		O
5		O
microM		O
.		O
The		O
dopaminergic		O
receptor		O
affinities		O
of		O
these		O
compounds		O
and		O
their		O
2		B-MODIFIER
-		I-MODIFIER
unsubstituted		I-MODIFIER
counterparts		I-MODIFIER
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
apomorphine		I-IUPAC
(		O
R		O
(		O
-		O
)		O
-		O
APO		O
,		O
R		O
-		O
1		O
)		O
,		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
apomorphine		I-IUPAC
(		O
S		O
(		O
+		O
)		O
-		O
APO		O
,		O
S		O
-		O
1		O
)		O
,		O
and		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylnorapomorphine		I-IUPAC
(		O
R		O
(		O
-		O
)		O
-		O
NPA		O
,		O
R		O
-		O
2		O
)		O
,		O
as		O
well		O
as		O
those		O
of		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroapomorphine		I-IUPAC
(		O
R		O
(		O
-		O
)		O
-		O
2		O
-		O
Cl		O
-		O
APO		O
,		O
R		O
-		O
6		O
)		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromoapomorphine		I-IUPAC
(		O
R		O
(		O
-		O
)		O
-		O
2		O
-		O
Br		O
-		O
APO		O
,		O
R		O
-		O
6		O
)		O
,		O
were		O
determined		O
with		O
tissue		O
membrane		O
preparations		O
of		O
corpus		O
striatum		O
from		O
rat		O
brain		O
.		O
Synthesis		O
and		O
antitetrabenazine		O
activity		O
of		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylmethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
piperidines		I-IUPAC
and		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenylpiperidines		I-IUPAC
,		O
prepared		O
as		O
simplified		O
and		O
possibly		O
more		O
readily		O
synthesized		O
analogues		O
of		O
3		B-IUPAC
-		I-IUPAC
phenylspiro		I-IUPAC
[		I-IUPAC
isobenzofuran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
piperidine		I-IUPAC
]		I-IUPAC
,		O
are		O
reported		O
.		O
The		O
diastereoisomers		O
were		O
separated		O
by		O
column		O
chromatography		O
and		O
the		O
camphanates		O
and		O
the		O
p		B-IUPAC
-		I-IUPAC
methoxybenzyl		I-IUPAC
group		B-MODIFIER
removed		O
by		O
saponification		O
and		O
acid		O
hydrolysis		O
,		O
respectively		O
,		O
for		O
each		O
diastereoisomer		O
to		O
give		O
the		O
enantiomers		O
of		O
2,4,5		B-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
myo		I-IUPAC
-		I-IUPAC
inositol		I-IUPAC
.		O
Compounds		O
in		O
series		O
3		O
tended		O
to		O
be		O
more		O
potent		O
,		O
10a		O
and		O
10c		O
having		O
scores		O
of		O
91		O
and		O
80%		O
,		O
respectively		O
.		O
The		O
transition		O
metal		O
complexes		O
[		B-IUPAC
eta		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2beta		I-IUPAC
-		I-IUPAC
carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
phenyltropane		I-IUPAC
)		I-IUPAC
]		I-IUPAC
tricarbonylchromium		I-IUPAC
(		O
3		O
)		O
and		O
[		B-IUPAC
eta		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2beta		I-IUPAC
-		I-IUPAC
carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
phenyltropane		I-IUPAC
)		I-IUPAC
]		I-IUPAC
[		I-IUPAC
eta		I-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
pentamethylcyclopentadienyl		I-IUPAC
)		I-IUPAC
]		I-IUPAC
ruthenium		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
triflate		I-IUPAC
(		O
4		O
)		O
were		O
synthesized		O
from		O
2beta		B-IUPAC
-		I-IUPAC
carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
phenyltropane		I-IUPAC
(		O
2		O
,		O
WIN		O
35,065		O
)		O
to		O
further		O
elucidate		O
the		O
influence		O
of		O
substituents		O
on		O
the		O
3beta		O
-		O
aryl		O
on		O
the		O
affinity		O
of		O
the		O
ligand		O
for		O
cocaine		O
-		O
binding		O
sites		O
at		O
the		O
dopamine		O
transporter		O
.		O
We		O
conclude		O
that		O
two		O
of		O
the		O
novel		O
adenosine		O
derivatives		O
revealed		O
herein		O
,		O
12		B-PARTIUPAC
and		O
5'		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
piperidinyl		I-IUPAC
]		I-IUPAC
adenosine		I-IUPAC
(		O
NNC		O
21-0147		O
,		O
13		O
)		O
,		O
representatives		O
of		O
a		O
new		O
series		O
of		O
P		O
(		O
1		O
)		O
ligands		O
,		O
reinforce		O
the		O
fact		O
that		O
novel		O
selective		O
adenosine		O
A		O
(		O
1		O
)		O
agonists		O
have		O
potential		O
in		O
the		O
treatment		O
of		O
cerebral		O
ischemia		O
in		O
humans		O
.		O
Approximately		O
one		O
-		O
third		O
of		O
the		O
compounds		O
examined		O
exhibited		O
activity		O
against		O
both		O
maximal		O
electroshock		O
-		O
and		O
pentylenetetrazole		O
-		O
induced		O
seizures		O
in		O
mice		O
.		O
Further		O
21a		O
was		O
shown		O
to		O
be		O
highly		O
selective		O
and		O
competitive		O
ACE		O
inhibitor		O
.		O
The		O
potency		O
and		O
selectivity		O
shown		O
by		O
some		O
of		O
these		O
ligands		O
for		O
the		O
NET		O
,		O
serotonine		O
transporter		O
(		O
SERT		O
)		O
,		O
or		O
NET		O
/		O
SERT		O
is		O
striking		O
,		O
particularly		O
in		O
view		O
of		O
the		O
displacement		O
of		O
the		O
aromatic		O
ring		O
in		O
this		O
series		O
from		O
its		O
usual		O
position		O
at		O
C		O
-		O
3		O
in		O
the		O
WIN		O
analogues		O
.		O
Internitrogen		O
spacings		O
had		O
a		O
large		O
effect		O
on		O
binding		O
affinity		O
and		O
subtype		O
selectivity		O
.		O
Here		O
we		O
report		O
the		O
syntheses		O
of		O
three		O
kinds		O
of		O
novel		O
2		B-IUPAC
-		I-IUPAC
aminothiophenes		I-IUPAC
and		O
assays		O
of		O
their		O
AE		O
activity		O
at		O
the		O
human		O
A		O
(		O
1		O
)		O
AR		O
(		O
hA		O
(		O
1		O
)		O
AR		O
)		O
,		O
namely		O
,		O
(		O
1		O
)		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
diphenylthiophene		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylates		I-IUPAC
,		O
3a		O
-		O
h		O
,		O
(		O
2		O
)		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
diphenylthiophenes		I-IUPAC
,		O
7a		O
-		O
p		O
,		O
and		O
(		O
3		O
)		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzoyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenylthiophenes		I-IUPAC
,		O
10a		O
-		O
h		O
.		O
X		O
-		O
ray		O
crystal		O
structures		O
were		O
determined		O
for		O
the		O
three		O
NHMe		O
derivatives		O
2		O
,		O
3		O
,		O
and		O
5c		O
in		O
the		O
pyrido		B-PARTIUPAC
[		I-PARTIUPAC
9,2		I-PARTIUPAC
-		I-PARTIUPAC
d		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
,		I-PARTIUPAC
pyrido		I-PARTIUPAC
[		I-PARTIUPAC
3,4		I-PARTIUPAC
-		I-PARTIUPAC
d		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
pyrimido		B-IUPAC
[		I-IUPAC
5,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
-		I-IUPAC
pyrimidine		I-IUPAC
series		B-MODIFIER
,		O
respectively		O
.		O
Antagonists		O
at		O
the		O
1A		O
/		O
2B		O
subtype		O
of		O
the		O
NMDA		O
receptor		O
(		O
NR1A		O
/		O
2B		O
)		O
are		O
typically		O
small		O
molecules		O
that		O
consist		O
of		O
a		O
4		B-PARTIUPAC
-		I-PARTIUPAC
benzyl		I-PARTIUPAC
-		I-PARTIUPAC
or		O
a		O
4		B-IUPAC
-		I-IUPAC
phenylpiperidine		I-IUPAC
with		O
an		O
omega		B-IUPAC
-		I-IUPAC
phenylalkyl		I-IUPAC
substituent		B-MODIFIER
on		O
the		O
heterocyclic		O
nitrogen		O
.		O
These		O
results		O
strengthen		O
the		O
requirement		O
of		O
an		O
enamino		O
ester		O
for		O
binding		O
to		O
the		O
dihydropyridine		O
receptor		O
and		O
indicate		O
a		O
nonspecific		O
role		O
for		O
the		O
N3		O
-		O
substituent		O
.		O
mansoni		O
in		O
vivo		O
.		O
Condensation		O
of		O
14		B-IUPAC
-		I-IUPAC
bromodaunorubicin		I-IUPAC
with		O
thiols		O
in		O
methanol		O
,		O
in		O
the		O
presence		O
of		O
potassium		O
carbonate		O
,		O
resulted		O
in		O
the		O
formation		O
of		O
14		O
-		O
thia		O
analogues		O
of		O
the		O
antitumor		O
antibiotic		O
adriamycin		O
.		O
The		O
peripheral		O
benzodiazepine		O
receptor		O
(		O
PBR		O
)		O
is		O
widely		O
expressed		O
in		O
peripheral		O
tissues		O
,		O
blood		O
cells		O
,		O
and		O
in		O
glia		O
cells		O
in		O
the		O
brain		O
.		O
This		O
eutomer		O
was		O
tested		O
on		O
two		O
algesiometric		O
paradigms		O
and		O
,		O
because		O
of		O
the		O
interaction		O
with		O
alpha2		O
-		O
adrenoreceptors		O
,		O
showed		O
a		O
potent		O
and		O
long		O
-		O
lasting		O
antinociceptive		O
activity		O
,		O
since		O
it		O
was		O
abolished		O
by		O
the		O
selective		O
alpha2		O
-		O
antagonist		O
RX821002		O
.		O
Among		O
the		O
analogues		B-MODIFIER
,		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chlorobenzylamino		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
cyclopropane		I-IUPAC
(		O
11a		O
)		O
with		O
the		O
(		B-IUPAC
1R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
cyclopropane		I-IUPAC
structure		B-MODIFIER
has		O
remarkable		O
antagonistic		O
activity		O
to		O
both		O
the		O
H3		O
(		O
Ki		O
=		O
8.4		O
nM		O
)		O
and		O
H4		O
(		O
Ki		O
=		O
7.6		O
nM		O
)		O
receptors		O
.		O
Compounds		O
with		O
substituents		O
(		O
F		O
,		O
CF3		O
)		O
in		O
the		O
4		O
-		O
or		O
7		O
-		O
position		O
of		O
the		O
isobenzofuran		O
display		O
high		O
affinity		O
for		O
sigma		O
2		O
binding		O
sites		O
(		O
IC50		O
(		O
sigma		O
2		O
)		O
=		O
0.5-2		O
nM		O
)		O
and		O
very		O
low		O
affinity		O
for		O
sigma		O
1		O
binding		O
sites		O
(		O
IC50		O
(		O
sigma		O
1		O
)		O
&		O
gt		O
;		O
100		O
nM		O
)		O
.		O
Investigation		O
of		O
(		B-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
difluorocyclopentyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylacetamides		I-IUPAC
containing		O
a		O
phenyl		B-IUPAC
or		O
heterocyclic		B-IUPAC
ring		B-MODIFIER
as		O
the		O
piperidinyl		B-IUPAC
side		B-MODIFIER
chain		I-MODIFIER
in		O
place		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pentenyl		I-IUPAC
moiety		B-MODIFIER
of		O
15a		O
revealed		O
that		O
this		O
acid		O
moiety		O
was		O
a		O
versatile		O
template		O
for		O
improving		O
the		O
selectivity		O
for		O
M		O
(		O
3		O
)		O
over		O
M		O
(		O
2		O
)		O
receptors		O
in		O
comparison		O
with		O
the		O
corresponding		O
cyclopentylphenylacetic		O
acid		O
group		O
.		O
Surprisingly		O
,		O
3beta		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2beta		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
isoxazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
tropane		I-IUPAC
(		O
3p		O
)		O
and		O
3beta		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2beta		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
isoxazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
tropane		I-IUPAC
(		O
3r		O
)		O
did		O
not		O
produce		O
significant		O
increases		O
in		O
locomotor		O
activity		O
.		O
The		O
structural		O
assignment		O
of		O
7,8		O
,		O
and		O
20a		O
were		O
made		O
by		O
single		O
-		O
crystal		O
X		O
-		O
ray		O
analysis		O
,		O
and		O
along		O
with		O
pyrazofurin		O
,		O
their		O
intramolecular		O
hydrogen		O
bond		O
characteristics		O
have		O
been		O
studied		O
.		O
Ligands		O
[		O
(		O
11		O
)		O
C		O
]		O
3		O
,		O
[		O
(		O
11		O
)		O
C		O
]		O
7		O
,		O
and		O
[		O
(		O
11		O
)		O
C		O
]		O
8		O
were		O
synthesized		O
by		O
alkylation		O
of		O
phenol		O
precursor		O
9		O
with		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
]		I-IUPAC
iodopropane		I-IUPAC
(		O
[		O
(		O
11		O
)		O
C		O
]		O
10		O
)		O
,		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
]		I-IUPAC
iodoethane		I-IUPAC
(		O
[		O
(		O
11		O
)		O
C		O
]		O
11		O
)		O
,		O
and		O
[		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
]		I-IUPAC
iodomethane		I-IUPAC
(		O
[		O
(		O
11		O
)		O
C		O
]		O
12		O
)		O
,		O
respectively		O
.		O
Sulfur		O
-		O
bridged		O
pregnanes		O
6,19		B-IUPAC
-		I-IUPAC
epithioprogesterone		I-IUPAC
,		O
21		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
6,19		I-IUPAC
-		I-IUPAC
epithioprogesterone		I-IUPAC
,		O
and		O
the		O
corresponding		O
sulfoxides		O
and		O
sulfones		O
were		O
synthesized		O
and		O
tested		O
as		O
blockers		O
of		O
the		O
immunosuppresive		O
activity		O
of		O
dexamethasone		O
in		O
rat		O
thymocytes		O
.		O
The		O
retention		O
of		O
glycine		O
/		O
NMDA		O
antagonist		O
activity		O
in		O
heterocyclic		O
ring		O
modified		O
analogues		O
,		O
such		O
as		O
the		O
oxanilide		O
69		O
and		O
the		O
2		B-IUPAC
-		I-IUPAC
carboxybenzimidazole		I-IUPAC
70		O
,		O
suggests		O
that		O
the		O
4		B-IUPAC
-		I-IUPAC
oxo		I-IUPAC
tautomer		B-MODIFIER
of		O
1		O
and		O
its		O
derivatives		O
is		O
required		O
for		O
activity		O
.		O
Both		O
systems		O
compare		O
the		O
ability		O
of		O
chelators		O
to		O
remove		O
iron		O
from		O
the		O
liver		O
,		O
the		O
prime		O
target		O
organ		O
in		O
thalassemia		O
.		O
Molecular		O
mechanics		O
calculations		O
with		O
AMBER		O
show		O
that		O
the		O
two		O
species		O
with		O
the		O
thermodynamically		O
most		O
favorable		O
binding		O
energies		O
are		O
the		O
11R		O
,		O
11aS		O
and		O
11S		O
,		O
11aS		O
isomers		O
with		O
their		O
aromatic		O
rings		O
to		O
the		O
5'		O
and		O
3'		O
sides		O
of		O
the		O
covalently		O
bound		O
guanine		O
,		O
respectively		O
.		O
Of		O
the		O
compounds		O
tested		O
for		O
duration		O
of		O
action		O
(		O
1		O
,		O
3-6		O
,		O
8		O
)		O
,		O
we		O
found		O
6		O
and		O
8		O
to		O
be		O
slightly		O
longer		O
-		O
acting		O
than		O
astressin		O
or		O
[		O
DHis32		O
]		O
astressin		O
,		O
while		O
their		O
potencies		O
in		O
vitro		O
were		O
not		O
significantly		O
different		O
from		O
that		O
of		O
3		O
.		O
3		B-IUPAC
-		I-IUPAC
Methoxy		I-IUPAC
-		I-IUPAC
4,5,6,7		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
benzisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
20a		O
)		O
,		O
or		O
the		O
corresponding		O
3		B-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
analogue		B-MODIFIER
(		O
20b		O
)		O
,		O
and		O
3		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4,5,6		I-IUPAC
,		I-IUPAC
7		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
benzisothiazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
51		O
)		O
were		O
synthesized		O
by		O
regioselective		O
chromic		O
acid		O
oxidation		O
of		O
the		O
respective		O
bicyclic		O
tetrahydrobenzenes		O
19a		O
,		O
b		O
and		O
50		O
,		O
and		O
they		O
were		O
used		O
as		O
key		O
intermediates		O
for		O
the		O
syntheses		O
of		O
the		O
target		O
zwitterionic		O
3		B-IUPAC
-		I-IUPAC
isoxazolols		I-IUPAC
8-15		O
and		O
3		B-IUPAC
-		I-IUPAC
isothiazolols		I-IUPAC
16		O
and		O
17		O
,		O
respectively		O
.		O
All		O
compounds		O
investigated		O
exhibited		O
low		O
host		O
cell		O
toxicity		O
to		O
several		O
stationary		O
and		O
proliferating		O
host		O
cell		O
lines		O
as		O
well		O
as		O
mitogen		O
-		O
stimulated		O
proliferating		O
human		O
T		O
lymphocytes		O
.		O
Both		O
3		O
and		O
4		O
were		O
folylpolyglutamate		O
synthetase		O
(		O
FPGS		O
)		O
substrates		O
.		O
Differential		O
scanning		O
calorimetry		O
has		O
been		O
used		O
to		O
investigate		O
the		O
phase		O
behavior		O
of		O
the		O
lipid		O
bilayers		O
.		O
Despite		O
the		O
high		O
affinity		O
of		O
the		O
dextrorotatory		O
derivatives		O
for		O
the		O
mu		O
opioid		O
receptor		O
,		O
the		O
high		O
affinity		O
and		O
selectivity		O
for		O
sigma		O
2		O
over		O
sigma		O
1		O
sites		O
will		O
surely		O
prove		O
beneficial		O
as		O
tools		O
for		O
the		O
delineation		O
of		O
the		O
function		O
and		O
physiological		O
role		O
of		O
sigma		O
2		O
receptors		O
.		O
The		O
[		O
2,3		O
-		O
dehydro		O
-		O
MeVal		O
(		O
9		O
)		O
]		O
-		O
AbA		O
was		O
the		O
most		O
potent		O
Pgp		O
inhibitory		O
aureobasidin		O
,		O
being		O
13		O
-		O
fold		O
more		O
potent		O
than		O
AbA		O
and		O
19		O
-		O
fold		O
more		O
potent		O
(		O
on		O
a		O
molar		O
basis		O
)		O
than		O
CsA		O
.		O
The		O
results		O
favor		O
the		O
hypothesis		O
that		O
weakly		O
polar		O
pi		O
-		O
pi		O
interactions		O
exist		O
between		O
the		O
aromatic		O
group		O
and		O
the		O
receptor		O
.		O
By		O
variation		O
of		O
the		O
substituents		O
in		O
the		O
benzene		O
part		O
of		O
the		O
indole		O
nucleus		O
in		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3-4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
piperidinyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
imidazolidinones		I-IUPAC
,		O
the		O
highest		O
5		O
-		O
HT2		O
receptor		O
affinity		O
and		O
selectivity		O
with		O
respect		O
to		O
dopamine		O
D2		O
receptors		O
and		O
alpha		O
1		O
adrenoceptors		O
were		O
obtained		O
by		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
substitution		B-MODIFIER
.		O
Included		O
within		O
this		O
group		O
are		O
examples		O
of		O
2		B-IUPAC
-		I-IUPAC
pyridylimidazopyridines		I-IUPAC
and		O
halo		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2		B-IUPAC
-		I-IUPAC
pyridylbenzimidazoles		I-IUPAC
.		O
The		O
hydrogen		O
-		O
bond		O
-		O
acceptor		O
properties		O
of		O
the		O
carbonyl		B-IUPAC
moiety		B-MODIFIER
in		O
the		O
17beta		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
group		B-MODIFIER
on		O
the		O
D		O
-		O
ring		O
of		O
the		O
anesthetic		O
steroids		O
(		B-PARTIUPAC
3alpha		I-PARTIUPAC
,		I-PARTIUPAC
5alpha		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
3alpha		I-IUPAC
,		I-IUPAC
5beta		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxypregan		I-IUPAC
-		I-IUPAC
20		I-IUPAC
-		I-IUPAC
one		I-IUPAC
form		O
an		O
important		O
part		O
of		O
the		O
anesthetic		O
steroid		O
pharmacophore		O
.		O
A		O
number		O
of		O
agents		O
,		O
most		O
notably		O
14		B-IUPAC
-		I-IUPAC
(		I-IUPAC
carbethoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
14		I-IUPAC
-		I-IUPAC
thiaadriamycin		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
14		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
14		I-IUPAC
-		I-IUPAC
selenaadriamycin		I-IUPAC
,		O
were		O
active		O
against		O
murine		O
L1210		O
leukemia		O
in		O
vivo		O
.		O
Various		O
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
3		B-PARTIUPAC
-		I-PARTIUPAC
alkylamino		I-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
alkoxy		I-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
alkylthio		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
sulfamoylbenzoic		I-IUPAC
acids		I-IUPAC
related		O
to		O
known		O
aminobenzoic		O
acid		O
diuretics		O
were		O
synthesized		O
and		O
screened		O
for		O
their		O
diuretic		O
properties		O
in		O
dogs		O
.		O
DNA		O
-		O
PK		O
inhibitory		O
activity		O
varied		O
widely		O
over		O
the		O
series		O
of		O
compounds		O
evaluated		O
(		O
IC		O
(		O
50		O
)		O
values		O
ranged		O
from		O
0.19		O
to		O
&		O
gt		O
;		O
10		O
microM		O
)		O
,		O
with		O
excellent		O
activity		O
being		O
observed		O
for		O
the		O
7,8		B-IUPAC
-		I-IUPAC
benzochromen		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
and		O
pyrimido		B-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
isoquinolin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
templates		O
.		O
It		O
is		O
likely		O
that		O
the		O
lowered		O
affinity		O
in		O
this		O
bicyclo		B-IUPAC
[		I-IUPAC
3.1.0		I-IUPAC
]		I-IUPAC
hexane		I-IUPAC
series		B-MODIFIER
is		O
a		O
consequence		O
of		O
nonoptimal		O
geometry		O
(		O
pseudoequatorial		O
phenyl		O
or		O
pseudoboat		O
)		O
for		O
binding		O
as		O
opposed		O
to		O
the		O
presence		O
of		O
steric		O
bulk		O
which		O
proved		O
deleterious		O
in		O
the		O
methylcyclohexyl		O
-		O
PCP		O
derivatives		O
.		O
For		O
the		O
syntheses		O
,		O
2,4		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
trimethylsily		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluorouracil		I-IUPAC
(		O
Me3Si		O
-		O
FU		O
,		O
1		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
acetoxytetrahydrofuran		I-IUPAC
(		O
Thf		O
-		O
OAc		O
,		O
2		O
)		O
were		O
condensed		O
in		O
the		O
presence		O
of		O
Friedel		O
-		O
Crafts		O
catalysts		O
,		O
such		O
as		O
SnCl4		O
and		O
BF3		O
-		O
Et2O		O
in		O
dichloromethane		O
,		O
or		O
in		O
the		O
presence		O
of		O
NaI		O
in		O
acetonitrile		O
to		O
give		O
Thf		O
-		O
Fu		O
or		O
Thf2		O
-		O
FU		O
depending		O
on		O
the		O
reaction		O
conditions		O
and		O
workup		O
procedure		O
.		O
The		O
synthesis		O
of		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
thienylvinyl		I-IUPAC
)		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiazoles		I-IUPAC
and		O
6		B-IUPAC
-		I-IUPAC
thienylimidazo		I-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thiazoles		I-IUPAC
is		O
reported		O
.		O
The		O
calculations		O
revealed		O
an		O
REV		O
region		O
located		O
near		O
the		O
top		O
of		O
the		O
carbocyclic		O
ring		O
in		O
the		O
bottom		O
face		O
of		O
the		O
molecule		O
.		O
All		O
the		O
2		B-IUPAC
-		I-IUPAC
indanylamides		I-IUPAC
6		O
and		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
indanylamides		I-IUPAC
8		O
were		O
devoid		O
of		O
any		O
appreciable		O
affinity		O
.		O
Glycosylation		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
bromopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
14		O
)		O
with		O
4		O
and		O
subsequent		O
debenzoylation		O
gave		O
3		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
ribonucleoside		B-MODIFIER
(		O
13a		O
)		O
from		O
which		O
3,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosylpyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
13b		O
)		O
was		O
obtained		O
by		O
amination		O
.		O
Our		O
SAR		O
studies		O
also		O
reveal		O
that		O
an		O
arenecarboxylic		O
acid		O
,		O
or		O
an		O
enoic		O
acid		O
in		O
which		O
the		O
carboxyl		B-IUPAC
group		B-MODIFIER
is		O
conjugated		O
with		O
the		O
central		O
ring		O
,		O
is		O
the		O
preferred		O
polar		O
group		O
.		O
Additionally		O
,		O
these		O
compounds		O
had		O
relatively		O
high		O
affinity		O
for		O
serotonin		O
5		O
-		O
HT1A		O
and		O
5		O
-		O
HT2A		O
,		O
dopamine		O
D2		O
,		O
and		O
adrenergic		O
alpha		O
1		O
receptors		O
.		O
A		O
series		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		O
substituted		B-MODIFIER
4		B-IUPAC
-		I-IUPAC
phenylpiperidines		I-IUPAC
,		O
4		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyridines		I-IUPAC
,		O
and		O
4		B-IUPAC
-		I-IUPAC
phenylpiperazines		I-IUPAC
was		O
synthesized		O
.		O
The		O
beta		O
-		O
keto		O
derivative		O
was		O
converted		O
by		O
reaction		O
with		O
MeMgBr		O
,		O
and		O
after		O
reaction		O
with		O
thymine		O
and		O
subsequent		O
deprotection		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
threo		I-IUPAC
-		I-IUPAC
pentofuranosyl		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
and		O
its		O
beta		O
-		O
anomer		O
were		O
obtained		O
.		O
All		O
compounds		O
were		O
tested		O
for		O
their		O
ability		O
to		O
inhibit		O
monoamine		O
reuptake		O
under		O
identical		O
conditions		O
.		O
In		O
conclusion		O
,		O
these		O
series		O
of		O
flavonoids		O
provide		O
leads		O
for		O
the		O
development		O
of		O
novel		O
potent		O
and		O
subtype		O
selective		O
A3		O
antagonists		O
.		O
Yet		O
,		O
the		O
L		O
-		O
Phe		O
content		O
increased		O
,		O
indicating		O
that		O
a		O
covalent		O
bond		O
had		O
been		O
formed		O
between		O
the		O
inhibitor		O
and		O
the		O
enzyme		O
.		O
Each		O
of		O
the		O
isozymes		O
demonstrated		O
a		O
high		O
degree		O
of		O
substrate		O
enantioselectivity		O
,		O
with		O
transferase		O
A		O
being		O
the		O
most		O
enantioselective		O
isozyme		O
.		O
The		O
1,2		B-IUPAC
-		I-IUPAC
dihydropyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyrazines		I-IUPAC
(		O
1		O
)		O
are		O
mitotic		O
inhibitors		O
with		O
significant		O
antitumor		O
activity		O
in		O
mice		O
.		O
Treatment		O
of		O
7,12		B-IUPAC
-		I-IUPAC
benz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthraquinone		I-IUPAC
(		O
2		O
)		O
with		O
methylmagnesium		O
iodide		O
or		O
methyllithium		O
yields		O
mixtures		O
of		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
dimethylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracenes		I-IUPAC
(		O
3a		O
,		O
b		O
)		O
,		O
in		O
which		O
the		O
ratio		O
of		O
cis		O
to		O
trans		O
lies		O
in		O
the		O
3		O
-		O
-		O
4		O
:		O
1		O
region		O
.		O
Structure		O
-		O
activity		O
relationships		O
are		O
discussed		O
.		O
Through		O
this		O
series		O
of		O
analyses		O
,		O
it		O
was		O
concluded		O
that		O
hydrophilic		O
interaction		O
of		O
a		O
4beta		B-IUPAC
,		I-IUPAC
19		I-IUPAC
-		I-IUPAC
diol		I-IUPAC
function		B-MODIFIER
with		O
the		O
active		O
site		O
of		O
aromatase		O
plays		O
a		O
critical		O
role		O
in		O
the		O
tight		O
binding		O
of		O
3		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ene		I-IUPAC
steroids		B-MODIFIER
.		O
Replacement		O
of		O
the		O
polar		O
head		O
of		O
our		O
previous		O
series		O
of		O
1		B-IUPAC
-		I-IUPAC
acyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cyanomethyl		I-IUPAC
]		I-IUPAC
piperazines		I-IUPAC
with		O
a		O
2		B-IUPAC
-		I-IUPAC
methylimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
group		B-MODIFIER
has		O
led		O
to		O
the		O
identification		O
of		O
a		O
new		O
series		O
of		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
acyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
derivatives		B-MODIFIER
as		O
potent		O
,		O
orally		O
active		O
platelet		O
-		O
activating		O
factor		O
(		O
PAF		O
)		O
antagonists		O
.		O
The		O
10		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
and		O
10		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
analogues		B-MODIFIER
gave		O
the		O
highest		O
percent		O
increases		O
in		O
life		O
span		O
for		O
mice		O
infected		O
with		O
L1210		O
leukemia		O
with		O
ILS		O
values		O
of		O
+		O
203		O
and		O
+		O
235%		O
,		O
respectively		O
.		O
A		O
similarly		O
reactive		O
intermediate		O
was		O
prepared		O
from		O
5		O
and		O
an		O
equimolar		O
amount		O
of		O
phosgene		O
in		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylacetamide		I-IUPAC
.		O
Tests		O
of		O
the		O
cytotoxicity		O
of		O
these		O
agents		O
to		O
oxygenated		O
and		O
chronically		O
hypoxic		O
EMT6		O
tumor		O
cells		O
in		O
culture		O
demonstrated		O
that		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
anthraquinone		I-IUPAC
,		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylcarbamyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
anthraquinone		I-IUPAC
,		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
toluenesulfonyl		I-IUPAC
)		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
anthraquinone		I-IUPAC
,		O
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
methoxymethyl		I-IUPAC
)		I-IUPAC
anthraquinone		I-IUPAC
were		O
significantly		O
more		O
toxic		O
to		O
hypoxic		O
cells		O
than		O
to		O
their		O
normally		O
aerated		O
counterparts		O
.		O
Last		O
,		O
neither		O
compound		O
displayed		O
dose		O
-		O
dependent		O
activation		O
of		O
alpha4beta2		O
nAChRs		O
.		O
d		O
(		O
CH2		O
)		O
5		O
-		O
D		O
-		O
Phe2		O
,		O
Lys4AVP		O
and		O
other		O
position		O
-		O
4		O
analogues		O
with		O
side		O
-		O
chain		O
functional		O
groups		O
may		O
be		O
useful		O
covalent		O
ligands		O
with		O
which		O
to		O
probe		O
the		O
structural		O
characteristics		O
of		O
AVP		O
renal		O
and		O
vascular		O
receptors		O
.		O
Med.		O
Chem.		O
1982		O
,		O
25		O
,		O
337-339		O
)		O
,		O
which		O
is		O
free		O
of		O
sedative		O
and		O
alcohol		O
interaction		O
potential		O
as		O
measured		O
by		O
the		O
test		O
procedures		O
described		O
.		O
The		O
phenyl		B-IUPAC
group		B-MODIFIER
was		O
optionally		O
substituted		O
with		O
4		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
or		O
2		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
substituents		B-MODIFIER
.		O
Two		O
chlorodiarylindenes		O
were		O
isolated		O
as		O
thermolysis		O
products		O
of		O
the		O
DTACs		O
,		O
and		O
one		O
was		O
converted		O
to		O
a		O
phenol		O
by		O
hydrogenolysis		O
.		O
The		O
sulfur		O
-		O
containing		O
ring		O
is		O
in		O
a		O
distorted		O
half		O
-		O
chair		O
in		O
1b		O
and		O
the		O
methyl		O
carbon		O
C		O
(		O
12		O
)		O
is		O
shown		O
to		O
be		O
trans		O
to		O
H		O
(		O
13		O
)		O
at		O
the		O
C		O
(		O
11		O
)		O
-		O
C		O
(		O
13		O
)		O
bond		O
.		O
We		O
measured		O
receptor		O
binding		O
affinity		O
using		O
recombinant		O
RAR		O
alpha		O
,		O
-		O
beta		O
,		O
and		O
-		O
gamma		O
proteins		O
and		O
assessed		O
cellular		O
differentiating		O
activity		O
in		O
F9		O
murine		O
teratocarcinoma		O
cells		O
(		O
F9		O
cells		O
)		O
.		O
The		O
potency		O
of		O
the		O
newly		O
synthesized		O
analogues		O
was		O
determined		O
in		O
the		O
stimulation		O
of		O
phospholipase		O
C		O
through		O
activation		O
of		O
turkey		O
erythrocyte		O
P2Y		O
(		O
1		O
)		O
or		O
human		O
P2Y		O
(		O
1		O
)		O
and		O
P2Y		O
(		O
2		O
)		O
receptors		O
stably		O
expressed		O
in		O
astrocytoma		O
cells		O
.		O
Our		O
goal		O
is		O
to		O
utilize		O
antagonists		O
of		O
the		O
serotonin		O
-		O
producing		O
enzymes		O
(		O
tryptophan		O
hydroxylase		O
and		O
AADC		O
)		O
as		O
the		O
basis		O
for		O
a		O
chemotherapeutic		O
approach		O
to		O
the		O
treatment		O
of		O
carcinoid		O
tumors		O
,		O
a		O
rare		O
tumor		O
type		O
characterized		O
by		O
the		O
overproduction		O
of		O
serotonin		O
.		O
In		O
the		O
systems		O
examined		O
,		O
(		O
-		O
)		O
-		O
2		O
exhibited		O
the		O
highest		O
affinity		O
for		O
kappa		O
receptors		O
,		O
with		O
a		O
Ki		O
of		O
44		O
+		O
/		O
-		O
8		O
nM		O
.		O
Routes		O
were		O
developed		O
for		O
the		O
synthesis		O
of		O
congeners		O
of		O
3		O
by		O
cyclization		O
of		O
4		B-PARTIUPAC
-		I-PARTIUPAC
(		O
substituted		B-MODIFIER
amino		B-IUPAC
)		O
-		B-PARTIUPAC
5,6		I-PARTIUPAC
-		I-PARTIUPAC
diaminopyridines		I-PARTIUPAC
with		O
ethyl		O
orthoformate		O
.		O
Bromomethyl		O
intermediate		O
15		O
was		O
prepared		O
from		O
the		O
corresponding		O
hydroxymethyl		B-IUPAC
precursor		B-MODIFIER
14		O
by		O
treatment		O
with		O
48%		O
HBr		O
.		O
The		O
isomeric		B-MODIFIER
pivaloyloxymethyl		B-IUPAC
derivatives		B-MODIFIER
of		O
9		O
,		O
compounds		O
43		O
and		O
44		O
,		O
were		O
synthesized		O
and		O
tested		O
as		O
potential		O
prodrugs		O
in		O
the		O
isoniazide		O
animal		O
model		O
.		O
1-1		O
microM		O
range		O
against		O
13		O
cell		O
lines		O
(		O
52%		O
)		O
.		O
5		B-IUPAC
-		I-IUPAC
Thio		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarbonitrile		I-IUPAC
was		O
obtained		O
from		O
butyl		B-IUPAC
6		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
sulfoxide		I-IUPAC
(		O
2		O
)		O
by		O
nitrosation		O
and		O
dehydration		O
of		O
the		O
oxime		O
.		O
The		O
displacement		O
of		O
[		B-PARTIUPAC
125I		I-PARTIUPAC
]		I-PARTIUPAC
(		I-PARTIUPAC
S		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
6b		O
and		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
sulpiride		I-IUPAC
from		O
their		O
respective		O
binding		O
sites		O
in		O
striatal		O
rat		O
brain		O
homogenates		O
using		O
various		O
neuroleptic		O
agents		O
showed		O
that		O
(		O
S		O
)		O
-		O
6b		O
has		O
the		O
same		O
binding		O
profile		O
but		O
more		O
potent		O
binding		O
for		O
dopamine		O
D		O
-		O
2		O
receptors		O
than		O
has		O
sulpiride		O
.		O
These		O
novel		O
compounds		O
are		O
derivatives		O
of		O
nipecotic		O
acid		O
,		O
guvacine		O
,		O
and		O
homo		B-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
proline		I-IUPAC
,		O
substituted		O
at		O
the		O
nitrogen		O
of		O
these		O
amino		O
acids		O
by		O
various		O
lipophilic		O
moieties		O
such		O
as		O
(		B-IUPAC
10,11		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenz		I-IUPAC
[		I-IUPAC
b		I-IUPAC
,		I-IUPAC
f		I-IUPAC
]		I-IUPAC
azepin		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
alkoxyalkyl		I-IUPAC
or		O
(		B-IUPAC
10,11		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
a		I-IUPAC
,		I-IUPAC
d		I-IUPAC
]		I-IUPAC
cyclohepten		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ylidene		I-IUPAC
)		I-IUPAC
alkoxyalkyl		I-IUPAC
.		O
1,2		B-IUPAC
-		I-IUPAC
Diacetoxy		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
dihydroacronycine		I-IUPAC
(		O
17		O
)		O
was		O
the		O
most		O
active		O
,		O
all		O
the		O
treated		O
mice		O
being		O
tumor		O
-		O
free		O
on		O
day		O
23		O
.		O
An		O
axial		O
phenyl		B-MODIFIER
and		O
equatorial		B-MODIFIER
piperidine		B-IUPAC
ring		B-MODIFIER
with		O
the		O
nitrogen		O
lone		O
pair		O
of		O
electrons		O
antiperiplanar		O
to		O
the		O
phenyl		B-IUPAC
ring		B-MODIFIER
has		O
been		O
postulated		O
as		O
the		O
receptor		O
-		O
active		O
conformation		O
of		O
PCP		O
-		O
like		O
ligands		O
at		O
the		O
PCP		O
binding		O
site		O
.		O
The		O
corresponding		O
trans		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
analogs		B-MODIFIER
were		O
found		O
to		O
be		O
potent		O
D2		O
agonists		O
with		O
full		O
intrinsic		O
activity		O
.		O
A		O
series		O
of		O
compounds		O
related		O
to		O
ethyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
benzyloxybenzoate		I-IUPAC
was		O
synthesized		O
and		O
evaluated		O
for		O
potential		O
hypolipidemic		O
activity		O
in		O
rats		O
.		O
Ex		O
vivo		O
autoradiography		O
showed		O
that		O
the		O
[		O
(		O
11		O
)		O
C		O
]		O
ligands		O
preferably		O
distributed		O
in		O
the		O
olfactory		O
bulb		O
and		O
cerebellum		O
,		O
two		O
regions		O
with		O
richer		O
PBR		O
density		O
in		O
the		O
rat		O
brain		O
.		O
